Methods for improving the structure and function of arterioles

ABSTRACT

The present invention relates to the unexpected finding that vessels smaller than even the smallest arteries (i.e. arterioles) thicken, become dysfunctional and cause end organ damage to tissues as diverse as the brain and the kidney. This invention provides a method to improve the structure and function of arterioles and preserve the function of end organs such as the brain and kidney.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Divisional of U.S. Ser. No. 11/296,582, filed Dec.6, 2005, which claims benefit of and priority to U.S. Ser. No.60/634,318, filed on Dec. 6, 2004, both of which are incorporated hereinby reference in their entirety for all purposes.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSOREDRESEARCH AND DEVELOPMENT

This invention was made with Government support under Grant No. HL030568awarded by the National Institutes of Health. The Government has certainrights in this invention.

FIELD OF THE INVENTION

This invention pertains to the field of vascular medicine. Inparticular, this invention provides novel methods of improving arteriolestructure and function and thereby mitigating pathologies associatedwith impaired circulation.

BACKGROUND OF THE INVENTION

Arterioles, as described herein, are vessels in the arterial circulation(as opposed to the venous circulation) with a diameter (after perfusionfixation or in vivo) of <200 μM. There is an extensive literature onchanges in arterioles associated with hypertension, aging, subarachnoidhemorrhage, multi-infarct dementia, Alzheimer's disease, and chronickidney disease as well as in other conditions. It appears that a varietyof pathological conditions can result in thickening of these arteriolesaccompanied by a loss of normal vasoreactivity.

The normal response to a fall in blood pressure is vasodilation to allowresistance to decrease and maintain forward flow. Failure to be able tovasodilate arterioles in the face of a fall in blood pressure may resultin a fall in blood flow to the target organ. If the target organ is thebrain, the fall in forward blood flow can result in an infarct in theregion of the arterioles involved.

Since the arterioles are so small they ordinarily serve a small area ofthe brain and therefore the infarct is small and may only be perceivedas a “Senior Moment”. However, we believe the accumulation of such aseries of insults over time may lead to significant end organ damage.

The major treatments for prevention of such end organ damage includeblood pressure control and control of plasma glucose and lipid levels.The use of certain agents (e.g., statins) to improve the structure andfunction of small to large arteries has been known and assumed to relateto the ability of these agents to lower cholesterol and reduceinflammatory cell infiltration into the arteries (see, e.g., Schonbecket al. (2004) Circulation 109(21 Suppl 1): 1118-26).

SUMMARY OF THE INVENTION

The present invention relates to the unexpected finding that vesselssmaller than even the smallest arteries (i.e. arterioles) thicken,become dysfunctional and cause end organ damage to tissues as diverse asthe brain and the kidney. This invention provides a method to improvethe structure and function of arterioles and preserve the function ofend organs such as the brain and kidney.

Thus, in certain embodiments, this invention provides methods ofimproving arteriole structure and/or function. The methods typicallyinvolve administering to a mammal in need thereof one or more of theactive agents described herein typically, in a dosage sufficient toimprove arteriole structure or function. In various embodiments thearteriole is an arteriole in kidney and/or brain, and/or in alveoli. Themammal can be a human, e.g., a patient in need of such therapeutic orprophylactic treatment or a non-human. Thus, both medical and veterinaryapplications are considered. In various embodiments the mammal is ahuman diagnosed as having memory loss or impaired learning and/orimpaired kidney function, and/or impaired alveolar (lung) function. Incertain embodiments the mammal is a human not diagnosed as having or atrisk for atherosclerosis and/or associated pathology and/or not undertreatment for atherosclerosis and/or associated pathology. In variousembodiments the active agent (e.g., peptide and/or peptide mimeticand/or lipid) is in a unit dosage formulation. In various embodimentsthe active agent(s) are formulated for administration by a routeselected from the group consisting of oral administration, nasaladministration, rectal administration, intraperitoneal injection, andintravascular injection, subcutaneous injection, transcutaneousadministration, and intramuscular injection. In various embodiments themethod of administration is by a route selected from the groupconsisting of oral administration, nasal administration, rectaladministration, intraperitoneal injection, and intravascular injection,subcutaneous injection, transcutaneous administration, and intramuscularinjection. In certain embodiments the active agent(s) are selected fromthe group consisting of D4F, L4F, reverse D4F, reverse L4F, circularlypermuted D4F, circularly permuted L4F, circularly permuted reverse L4F,circularly permuted reverse D4F, and DMPC. In various embodiments theactive agent(s) are provided in combination with a pharmaceuticallyacceptable excipient.

In certain embodiments this invention also provides an active agent asdescribed herein for use in the prophylaxis or treatment of arterioleshaving impaired structure or function. Also provided is the use of anactive agent as described herein for the manufacture of a medicament forthe prophylaxis or treatment of arterioles having impaired structure orfunction.

Also provided are kits for the treatment of a condition characterized byabnormal arteriole structure or function. The kits typically compriseone or more containers containing the active agent(s) described hereinand instructional materials teaching the use of the active agent(s) inthe treatment of a condition characterized by abnormal arteriolestructure or function. In various embodiments the active agent (e.g.,peptide and/or peptide mimetic and/or lipid) is in a unit dosageformulation. In various embodiments the active agent(s) are formulatedfor administration by a route selected from the group consisting of oraladministration, nasal administration, rectal administration,intraperitoneal injection, and intravascular injection, subcutaneousinjection, transcutaneous administration, and intramuscular injection.In certain embodiments the active agent(s) are selected from the groupconsisting of D4F, L4F, reverse D4F, reverse L4F, circularly permutedD4F, circularly permuted L4F, circularly permuted reverse L4F,circularly permuted reverse D4F, and DMPC. In various embodiments theactive agent(s) are provided in combination with a pharmaceuticallyacceptable excipient.

DEFINITIONS

The terms “isolated”, “purified”, or “biologically pure” when referringto an isolated polypeptide refer to material that is substantially oressentially free from components that normally accompany it as found inits native state. With respect to nucleic acids and/or polypeptides theterm can refer to nucleic acids or polypeptides that are no longerflanked by the sequences typically flanking them in nature. Chemicallysynthesized polypeptides are “isolated” because they are not found in anative state (e.g. in blood, serum, etc.). In certain embodiments, theterm “isolated” indicates that the polypeptide is not found in nature.

The terms “polypeptide”, “peptide” and “protein” are usedinterchangeably herein to refer to a polymer of amino acid residues. Theterms apply to amino acid polymers in which one or more amino acidresidues is an artificial chemical analogue of a corresponding naturallyoccurring amino acid, as well as to naturally occurring amino acidpolymers.

The term “an amphipathic helical peptide” refers to a peptide comprisingat least one amphipathic helix (amphipathic helical domain). Certainamphipathic helical peptides of this invention can comprise two or more(e.g. 3, 4, 5, etc.) amphipathic helices.

The term “class A amphipathic helix” refers to a protein structure thatforms an α-helix producing a segregation of a polar and nonpolar faceswith the positively charged residues residing at the polar-nonpolarinterface and the negatively charged residues residing at the center ofthe polar face (see, e.g., “Segrest et al. (1990) Proteins: Structure,Function, and Genetics 8: 103-117).

“Apolipoprotein J” (apo J) is known by a variety of names includingclusterin, TRPM2, GP80, and SP 40,40 (Fritz (1995) Pp 112 In: Clusterin:Role in Vertebrate Development, Function, and Adaptation (Harmony JAKEd.), R. G. Landes, Georgetown, Tex.,). It was first described as aheterodimeric glycoprotein and a component of the secreted proteins ofcultured rat Sertoli cells (Kissinger et al. (1982) Biol Reprod;27:233240). The translated product is a single-chain precursor proteinthat undergoes intracellular cleavage into a disulfide-linked 34 kDaαsubunit and a 47 kDa βsubunit Collard and Griswold (187) Biochem., 26:3297-3303). It has been associated with cellular injury, lipidtransport, apoptosis and it may be involved in clearance of cellulardebris caused by cell injury or death. Clusterin has been shown to bindto a variety of molecules with high affinity including lipids, peptides,and proteins and the hydrophobic probe 1-anilino-8-naphthalenesulfonate(Bailey et al. (2001) Biochem., 40: 11828-11840).

The class G amphipathic helix is found in globular proteins, and thus,the name class G. The feature of this class of amphipathic helix is thatit possesses a random distribution of positively charged and negativelycharged residues on the polar face with a narrow nonpolar face. Becauseof the narrow nonpolar face this class does not readily associate withphospholipid (see, Segrest et al. (1990) Proteins: Structure, Function,and Genetics. 8: 103-117; also see Erratum (1991) Proteins: Structure,Function and Genetics, 9: 79). Several exchangeable apolipoproteinspossess similar but not identical characteristics to the G amphipathichelix. Similar to the class G amphipathic helix, this other classpossesses a random distribution of positively and negatively chargedresidues on the polar face. However, in contrast to the class Gamphipathic helix which has a narrow nonpolar face, this class has awide nonpolar face that allows this class to readily bind phospholipidand the class is termed G* to differentiate it from the G class ofamphipathic helix (see Segrest et al. (1992) J. Lipid Res., 33: 141-166;also see Anantharamaiah et al. (1993) Pp. 109-142 In: The AmphipathicHelix, Epand, R. M. Ed CRC Press, Boca Raton, Fla.). Computer programsto identify and classify amphipathic helical domains have been describedby Jones et al. (1992) J. Lipid Res. 33: 287-296) and include, but arenot limited to the helical wheel program (WHEEL or WHEEL/SNORKEL),helical net program (HELNET, HELNET/SNORKEL, HELNET/Angle), program foraddition of helical wheels (COMBO or COMBO/SNORKEL), program foraddition of helical nets (COMNET, COMNET/SNORKEL, COMBO/SELECT,COMBO/NET), consensus wheel program (CONSENSUS, CONSENSUS/SNORKEL), andthe like.

The term “ameliorating” when used with respect to “ameliorating one ormore symptoms of atherosclerosis” refers to a reduction, prevention, orelimination of one or more symptoms characteristic of atherosclerosisand/or associated pathologies. Such a reduction includes, but is notlimited to a reduction or elimination of oxidized phospholipids, areduction in atherosclerotic plaque formation and rupture, a reductionin clinical events such as heart attack, angina, or stroke, a decreasein hypertension, a decrease in inflammatory protein biosynthesis,reduction in plasma cholesterol, and the like.

The term “enantiomeric amino acids” refers to amino acids that can existin at least two forms that are nonsuperimposable mirror images of eachother. Most amino acids (except glycine) are enantiomeric and exist in aso-called L-form (L amino acid) or D-form (D amino acid). Most naturallyoccurring amino acids are “L” amino acids. The terms “D amino acid” and“L amino acid” are used to refer to absolute configuration of the aminoacid, rather than a particular direction of rotation of plane-polarizedlight. The usage herein is consistent with standard usage by those ofskill in the art. Amino acids are designated herein using standard1-letter or three-letter codes, e.g. as designated in Standard ST.25 inthe Handbook On Industrial Property Information and Documentation.

The term “protecting group” refers to a chemical group that, whenattached to a functional group in an amino acid (e.g. a side chain, analpha amino group, an alpha carboxyl group, etc.) blocks or masks theproperties of that functional group. Preferred amino-terminal protectinggroups include, but are not limited to acetyl, or amino groups. Otheramino-terminal protecting groups include, but are not limited to alkylchains as in fatty acids, propeonyl, formyl and others. Preferredcarboxyl terminal protecting groups include, but are not limited togroups that form amides or esters.

The phrase “protect a phospholipid from oxidation by an oxidizing agent”refers to the ability of a compound to reduce the rate of oxidation of aphospholipid (or the amount of oxidized phospholipid produced) when thatphospholipid is contacted with an oxidizing agent (e.g. hydrogenperoxide, 13-(S)—HPODE, 15-(S)—HPETE, HPODE, HPETE, HODE, HETE, etc.).

The terms “low density lipoprotein” or “LDL” is defined in accordancewith common usage of those of skill in the art. Generally, LDL refers tothe lipid-protein complex which when isolated by ultracentrifugation isfound in the density range d=1.019 to d=1.063.

The terms “high density lipoprotein” or “HDL” is defined in accordancewith common usage of those of skill in the art. Generally “HDL” refersto a lipid-protein complex which when isolated by ultracentrifugation isfound in the density range of d=1.063 to d=1.21.

The term “Group I HDL” refers to a high density lipoprotein orcomponents thereof (e.g. apo A-I, paraoxonase, platelet activatingfactor acetylhydrolase, etc.) that reduce oxidized lipids (e.g. in lowdensity lipoproteins) or that protect oxidized lipids from oxidation byoxidizing agents.

The term “Group II HDL” refers to an HDL that offers reduced activity orno activity in protecting lipids from oxidation or in repairing (e.g.reducing) oxidized lipids.

The term “HDL component” refers to a component (e.g. molecules) thatcomprises a high density lipoprotein (HDL). Assays for HDL that protectlipids from oxidation or that repair (e.g. reduce oxidized lipids) alsoinclude assays for components of HDL (e.g. apo A-I, paraoxonase,platelet activating factor acetylhydrolase, etc.) that display suchactivity.

The term “human apo A-I peptide” refers to a full-length human apo A-Ipeptide or to a fragment or domain thereof comprising a class Aamphipathic helix.

A “monocytic reaction” as used herein refers to monocyte activitycharacteristic of the “inflammatory response” associated withatherosclerotic plaque formation. The monocytic reaction ischaracterized by monocyte adhesion to cells of the vascular wall (e.g.cells of the vascular endothelium), and/or chemotaxis into thesubendothelial space, and/or differentiation of monocytes intomacrophages.

The term “absence of change” when referring to the amount of oxidizedphospholipid refers to the lack of a detectable change, more preferablythe lack of a statistically significant change (e.g. at least at the85%, preferably at least at the 90%, more preferably at least at the95%, and most preferably at least at the 98% or 99% confidence level).The absence of a detectable change can also refer to assays in whichoxidized phospholipid level changes, but not as much as in the absenceof the protein(s) described herein or with reference to other positiveor negative controls.

The following abbreviations are used herein: PAPC:L-α-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine; POVPC:1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphocholine; PGPC:1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine; PEIPC:1-palmitoyl-2-(5,6-epoxyisoprostane E₂)-sn-glycero-3-phosphocholine; ChC18:2: cholesteryl linoleate; ChC18:2-OOH: cholesteryl linoleatehydroperoxide; DMPC: 1,2-ditetradecanoyl-rac-glycerol-3-phosphocholine;PON: paraoxonase; HPF: Standardized high power field; PAPC:L-α-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine; BL/6:C57BL/6J; C3H:C3H/HeJ.

The term “conservative substitution” is used in reference to proteins orpeptides to reflect amino acid substitutions that do not substantiallyalter the activity (specificity (e.g. for lipoproteins)) or bindingaffinity (e.g. for lipids or lipoproteins)) of the molecule. Typicallyconservative amino acid substitutions involve substitution one aminoacid for another amino acid with similar chemical properties (e.g.charge or hydrophobicity). The following six groups each contain aminoacids that are typical conservative substitutions for one another: 1)Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamicacid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K);5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6)Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

The terms “identical” or percent “identity,” in the context of two ormore nucleic acids or polypeptide sequences, refer to two or moresequences or subsequences that are the same or have a specifiedpercentage of amino acid residues or nucleotides that are the same, whencompared and aligned for maximum correspondence, as measured using oneof the following sequence comparison algorithms or by visual inspection.With respect to the peptides of this invention sequence identity isdetermined over the full length of the peptide.

For sequence comparison, typically one sequence acts as a referencesequence, to which test sequences are compared. When using a sequencecomparison algorithm, test and reference sequences are input into acomputer, subsequence coordinates are designated, if necessary, andsequence algorithm program parameters are designated. The sequencecomparison algorithm then calculates the percent sequence identity forthe test sequence(s) relative to the reference sequence, based on thedesignated program parameters.

Optimal alignment of sequences for comparison can be conducted, e.g., bythe local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482(1981), by the homology alignment algorithm of Needleman & Wunsch, J.Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson& Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444, by computerizedimplementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA inthe Wisconsin Genetics Software Package, Genetics Computer Group, 575Science Dr., Madison, Wis.), or by visual inspection (see generallyAusubel et al., supra).

One example of a useful algorithm is PILEUP. PILEUP creates a multiplesequence alignment from a group of related sequences using progressive,pairwise alignments to show relationship and percent sequence identity.It also plots a tree or dendogram showing the clustering relationshipsused to create the alignment. PILEUP uses a simplification of theprogressive alignment method of Feng & Doolittle (1987) J. Mol. Evol.35:351-360. The method used is similar to the method described byHiggins & Sharp (1989) CABIOS 5: 151-153. The program can align up to300 sequences, each of a maximum length of 5,000 nucleotides or aminoacids. The multiple alignment procedure begins with the pairwisealignment of the two most similar sequences, producing a cluster of twoaligned sequences. This cluster is then aligned to the next most relatedsequence or cluster of aligned sequences. Two clusters of sequences arealigned by a simple extension of the pairwise alignment of twoindividual sequences. The final alignment is achieved by a series ofprogressive, pairwise alignments. The program is run by designatingspecific sequences and their amino acid or nucleotide coordinates forregions of sequence comparison and by designating the programparameters. For example, a reference sequence can be compared to othertest sequences to determine the percent sequence identity relationshipusing the following parameters: default gap weight (3.00), default gaplength weight (0.10), and weighted end gaps.

Another example of algorithm that is suitable for determining percentsequence identity and sequence similarity is the BLAST algorithm, whichis described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410.Software for performing BLAST analyses is publicly available through theNational Center for Biotechnology Information(http://www.ncbi.nlm.nih.gov/). This algorithm involves firstidentifying high scoring sequence pairs (HSPs) by identifying shortwords of length W in the query sequence, which either match or satisfysome positive-valued threshold score T when aligned with a word of thesame length in a database sequence. T is referred to as the neighborhoodword score threshold (Altschul et al, supra). These initial neighborhoodword hits act as seeds for initiating searches to find longer HSPscontaining them. The word hits are then extended in both directionsalong each sequence for as far as the cumulative alignment score can beincreased. Cumulative scores are calculated using, for nucleotidesequences, the parameters M (reward score for a pair of matchingresidues; always >0) and N (penalty score for mismatching residues;always <0). For amino acid sequences, a scoring matrix is used tocalculate the cumulative score. Extension of the word hits in eachdirection are halted when: the cumulative alignment score falls off bythe quantity X from its maximum achieved value; the cumulative scoregoes to zero or below, due to the accumulation of one or morenegative-scoring residue alignments; or the end of either sequence isreached. The BLAST algorithm parameters W, T, and X determine thesensitivity and speed of the alignment. The BLASTN program (fornucleotide sequences) uses as defaults a wordlength (W) of 11, anexpectation (E) of 10, M=5, N=−4, and a comparison of both strands. Foramino acid sequences, the BLASTP program uses as defaults a wordlength(W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (seeHenikoff & Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915).

In addition to calculating percent sequence identity, the BLASTalgorithm also performs a statistical analysis of the similarity betweentwo sequences (see, e.g., Karlin & Altschul (1993) Proc. Natl. Acad.Sci. USA, 90: 5873-5787). One measure of similarity provided by theBLAST algorithm is the smallest sum probability (P(N)), which providesan indication of the probability by which a match between two nucleotideor amino acid sequences would occur by chance. For example, a nucleicacid is considered similar to a reference sequence if the smallest sumprobability in a comparison of the test nucleic acid to the referencenucleic acid is less than about 0.1, more preferably less than about0.01, and most preferably less than about 0.001.

A “circularly permuted protein” is one in the natural/original terminiof the protein are joined and the resulting circular protein is openedat another point to create new C- and N-termini. The circularly permutedprotein need not be created by an actual joining of termini and openingat another point, but may be synthesized/expressed de novo having asequence identical to a circularly permuted variant. Two proteins arerelated by a circular permutation (CP) when a fragment in the C-terminalpart of a first protein matches a fragment in the N-terminal part of asecond protein and a fragment in the N-terminal part of the firstprotein matches a fragment in the C-terminal part of the second protein.Methods of identifying circular permutations are known to those of skillin the art (see, e.g., Uliel et al. (1999) Bioinformatics, 15(11):930-936).

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A, 1B, and 1C show that mice with an absence of LDL receptors(LDLR−/−) have thickened brain arterioles compared to wild-type mice(WT). FIG. 1A: wall thickness of small arterioles (15-40 μm diameter);FIG. 1B: wall thickness in medium arterioles (41-80 μm diameter); FIG.1C: wall thickness in large arterioles (81-160 μm diameter).

FIG. 2 shows the results from a T-maze continuous alteration task(T-CAT) in LDR−/− mice on Western diet treated with D4F and “scrambled”D4F.

FIG. 3 shows the results from a T-maze continuous alteration task(T-CAT) in LDR−/− mice on Western diet treated with D4F and scrambled(sc D-4F) expressed as percentage alteration.

FIG. 4 illustrates improvement in a T-maze test by treatment with D4F.

FIG. 5 shows that oral DMPC improves vasoreactivity in LDL receptor nullmice on a Western diet.

FIGS. 6A-6C show that Brain arteriolar wall thickness (measured on H&Esections) is increased in LDL receptor null mice on chow (n=4) comparedto wild-type mice on chow (n=4) and is further increased with additionof the Western diet (n=4). FIG. 6A shows vessel wall thickness forarterioles with lumens 15-40 μm in diameter. FIG. 6B shows vessel wallthickness for arterioles with lumens 41-80 μm in diameter. FIG. 6C showsvessel wall thickness for vessels with lumens 81-160 μm in diameter. Thebar graphs show the Mean±SEM. WT, wild-type mice; LDL−/− Chow, LDLreceptor null mice on a chow diet; LDL−/− Western, LDL receptor nullmice on a Western diet for six weeks.

FIGS. 7A-7G show that brain arteriolar wall thickness (measured on H&Esections) is decreased in LDL receptor null mice on a Western diettreated with D-4F but not scrambled D-4F. LDL receptor null mice werefed a Western diet for six weeks and received either D-4F at 300 μg/mLin their drinking water (n=15) or scrambled D-4F (Sc D-4F) at 300 μg/mLin their drinking water (n=15). FIG. 7A shows vessel wall thickness forarterioles with lumens 10-20 μm in diameter. FIG. 7B shows vessel wallthickness for arterioles with lumens 21-50 μm in diameter. FIG. 7C showsvessel wall thickness for arterioles 51-100 μm in diameter. FIG. 7Dshows the arteriolar lumen diameters for the mice. FIG. 7E shows thewall thickness divided by the diameter of the lumen for arterioles 10-20μm in diameter. FIG. 7F shows the wall thickness divided by the diameterof the lumen for arterioles 21-50 μm in diameter. FIG. 7G shows the wallthickness divided by the diameter of the lumen for arterioles 51-100 μmin diameter. The bar graphs show the Mean±SEM for 15 mice in each group.

FIGS. 8A-8E show that brain arteriolar smooth muscle mactin is increasedby feeding LDL receptor null mice a Western diet and is reduced bytreatment with D-4F but not scrambled D-4F. FIG. 8A: LDL receptor nullmice were fed a chow (n=10) or Western diet (WD) (n=10) for six weeksand their brain arterioles were stained for smooth muscle α-actin andthe wall to lumen ratio calculated for each arteriole. The values shownare the Mean±SEM for 10 mice in each group. FIGS. 8B-8E. The brainarterioles of the mice described in FIG. 7 and Panel A of this Figurewere stained for smooth muscle α-actin. FIG. 8B: Examples of brainarterioles stained for smooth muscle α-actin. FIG. 8C: Wall to lumenratio of arterioles with lumens 10-20 μm in diameter from mice in FIG.7. FIG. 8D: Wall to lumen ratio of arterioles with lumens 21-50 μm indiameter from mice in FIG. 7. FIG. 8E: Wall to lumen ratio of arterioles51-100 μm in diameter from mice in FIG. 7. The bar graphs show theMean±SEM for 15 mice in each group.

FIGS. 9A-9G shows performance of LDL receptor null mice in the T-mazecontinuous alternation task (T-CAT) as a function of diet and treatment.FIG. 9A-9D: The mice described in FIG. 8A were tested by T-CAT forspatial memory performance. FIG. 9A: The number of spontaneousalternations was determined. The data are the Mean±SEM from 15 trialswith 10 mice in each group. FIG. 9B: The percent spontaneousalternations were determined. The data are the Mean±SEM from 15 trialswith 10 mice in each group. FIG. 9C: The spontaneous alternation ratedifferent from the 50% random choice was determined. The data are theMean±SEM from 15 trials with 10 mice in each group. FIG. 9D: The time tocomplete the trials was determined. The data are the Mean±SEM from 15trials with 10 mice in each group. FIGS. 9E-9G: The mice described inFIGS. 7 and 8B-8E were tested by T-CAT for spatial memory performance asdescribed above. FIG. 9E: The number of spontaneous alternations wasdetermined. The data are the Mean±SEM from 15 trials with 15 mice ineach group. FIG. 9F: The percent spontaneous alternations weredetermined. The data are the Mean±SEM from 15 trials with 15 mice ineach group. FIG. 9G: The spontaneous alternation rate different from the50% random choice was determined. The data are the Mean±SEM from 15trials with 15 mice in each group.

DETAILED DESCRIPTION

This invention pertains to the surprising finding that vessels smallerthan even the smallest arteries (i.e., arterioles) thicken, becomedysfunctional and cause end organ damage to tissues as diverse as thebrain and the kidney. This invention provides a method to improve thestructure and function of arterioles and preserve the function of endorgans such as the brain and kidney.

We reasoned that if the abnormalities that we had studied in largearteries would extend to small arteries and even to smaller vessels, thearterioles. Arterioles are vessels of less than about 200 μm moretypically less than about 100 μm in diameter. We also hypothesized thatif the beneficial effects of an apoA-I mimetic peptide (D-4F) were seenin both large arteries (Navab et al. (2002) Circulation, 105: 290-292;Van Lenten et al. (2002) Circulation, 106: 1127-1132) and small arteries(Ou et al. (2003) Circulation, 107: 2337-2341), the beneficial effectmight also be seen in arterioles. We report here that the walls of brainarterioles ranging from 10 to 100 μm in diameter are thickened in LDLreceptor null mice compared to wild-type, that the thickening isworsened with a Western diet and associated with decreased performancein the T-maze continuous alternation task. The increase in brainarteriolar wall thickness is due in part to an increase in brainarteriolar smooth muscle α-actin content and was significantly improvedwith D-4F treatment. It appears that treatment of LDL-receptor null micefed a Western Diet with D-4F reduces brain arteriolar wall thicknessindependent of plasma lipids and arteriolar lumen diameter and improvesspatial memory.

Accordingly, it is believed that use of D-4F, L-4F and other activeagents described herein peptides are effective to improve the structureand/or function of arterioles and thereby to ameliorate one or moresymptoms of a condition characterized by impaired arteriole structureand/or function. Such conditions include, for example, impairedneurological function (e.g., associated with Alzheimer's disease,Parkinsons disease, age related memory loss, stroke associated memoryloss, Benswanger's disease, and the like), impaired kidney function,impaired alveolar function, and the like.

In certain embodiments the present invention thus provides novel methodsfor improving the structure and function of arterioles by administeringone or more agents that sequester, and/or remove, and/or destroyinflammatory lipids and convert pro-inflammatory high densitylipoproteins (HDL) to anti-inflammatory or render anti-inflammatory HDLmore anti-inflammatory. These active agents include certain peptidescontaining a class A amphipathic helix (see, e.g., U.S. Pat. No.6,664,230, PCT Publications WO 2002/15923, and WO 2004/034977, andcopending applications U.S. Ser. Nos. 09/896,841, 10/187,215,10/273,386, and 10/423,830 which are incorporated herein by reference),peptides containing a G* amphipathic helix (see, e.g., PCT publicationWO 03/086,326, and copending U.S. application U.S. Ser. No. 10/120,508,which are incorporated herein by reference), short peptides andnon-peptides with a molecular weight of less than 900 daltons that havea solubility in ethyl acetate of at least 4 mg/mL, and which are solublein aqueous buffer at pH 7.0 and when contacted with a phospholipid in anaqueous environment, form particles with a diameter of approximately 7.5nm and form stacked bilayers with a bilayer dimension on the order of3.4 to 4.1 nm with spacing between the bilayers in the stack ofapproximately 2 nm (see, e.g., PCT/US2004/026288, copending U.S.applications U.S. Ser. No. 10/649,378, and 10/913,800 and copending U.S.application U.S. Ser. No. 60/600,925, respectively, which areincorporated herein by reference); and oral synthetic phospholipids inwhich the sn-1 and sn-2 positions are identical and contain at least 3carbons (see, e.g., copending U.S. application Ser. Nos. 09/539,569 and09/994,227, and PCT publication WO 01/75168, which are incorporatedherein by reference).

In certain embodiments, this invention is practiced by administering toa mammal (e.g., a human) one or more of the active agents describedherein (peptides, peptide mimetics, lipids, small organic molecules,etc.). The agent(s) are preferably administered in a dose or a dosageregimen sufficient to improve the structure and/or function ofarterioles, preferably arterioles having a diameter less than about 200μm, more preferably having a diameter less than about 160 μm, still morepreferably having a diameter less than about 80 μm, and most preferablyhaving a diameter less than about 50 μm or40 μm.

I. Active Agents.

A wide variety of active agents are suitable for the treatment of one ormore of the indications discussed above. These agents include, but arenot limited to class A amphipathic helical peptides, class A amphipathichelical peptide mimetics of apoA-I having aromatic or aliphatic residuesin the non-polar face, small peptides including penta-peptides,tetrapeptides, tripeptides, dipeptides and pairs of amino acids, Apo-J(G* peptides), and peptide mimetics, e.g., as described below.

A) Class a Amphipathic Helical Peptides.

In certain embodiments, the activate agents for use in the method ofthis invention include class A amphipathic helical peptides, e.g. asdescribed in U.S. Pat. No. 6,664,230, and PCT Publications WO 02/15923and WO 2004/034977. It was discovered that peptides comprising a class Aamphipathic helix (“class A peptides”), in addition to being capable ofmitigating one or more symptoms of atherosclerosis are also useful inthe treatment of one or more of the other indications described herein.

Class A peptides are characterized by formation of an α-helix thatproduces a segregation of polar and non-polar residues thereby forming apolar and a nonpolar face with the positively charged residues residingat the polar-nonpolar interface and the negatively charged residuesresiding at the center of the polar face (see, e.g., Anantharamaiah(1986) Meth. Enzymol, 128: 626-668). It is noted that the fourth exon ofapo A-I, when folded into 3.667 residues/turn produces a class Aamphipathic helical structure.

One class A peptide, designated 18A (see, e.g., Anantharamaiah (1986)Meth. Enzymol, 128: 626-668) was modified as described herein to producepeptides orally administratable and highly effective at inhibiting orpreventing one or more symptoms of atherosclerosis and/or otherindications described herein. Without being bound by a particulartheory, it is believed that the peptides of this invention may act invivo may by picking up seeding molecule(s) that mitigate oxidation ofLDL.

We determined that increasing the number of Phe residues on thehydrophobic face of 18A would theoretically increase lipid affinity asdetermined by the computation described by Palgunachari et al. (1996)Arteriosclerosis, Thrombosis, & Vascular Biology 16: 328-338.Theoretically, a systematic substitution of residues in the nonpolarface of 18A with Phe could yield six peptides. Peptides with anadditional 2, 3 and 4 Phe would have theoretical lipid affinity (λ)values of 13, 14 and 15 units, respectively. However, the λ valuesjumped four units if the additional Phe were increased from 4 to 5 (to19λ units). Increasing to 6 or 7 Phe would produce a less dramaticincrease (to 20 and 21λ units, respectively).

A number of these class A peptides were made including, the peptidedesignated 4F, D4F, 5F, and D5F, and the like. Various class A peptidesinhibited lesion development in atherosclerosis-susceptible mice. Inaddition, the peptides show varying, but significant degrees of efficacyin mitigating one or more symptoms of the various pathologies describedherein. A number of such peptides are illustrated in Table 1.

TABLE 1 Illustrative class A amphipathic helical peptides for use inthis invention. Peptide SEQ ID Name Amino Acid Sequence NO. 18A   D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F 1 2FAc-D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH₂ 2 3FAc-D-W-F-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH₂ 3 3F14Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH₂ 4 4FAc-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH₂ 5 5FAc-D-W-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-NH₂ 6 6FAc-D-W-L-K-A-F-Y-D-K-F-F-E-K-F-K-E-F-F-NH₂ 7 7FAc-D-W-F-K-A-F-Y-D-K-F-F-E-K-F-K-E-F-F-NH₂ 8Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-F-F-NH₂ 9Ac-D-W-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-A-F-NH₂ 10Ac-D-W-L-K-A-F-Y-D-K-V-F-E-K-L-K-E-F-F-NH₂ 11Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-F-F-NH₂ 12Ac-D-W-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-NH₂ 13Ac-E-W-L-K-L-F-Y-E-K-V-L-E-K-F-K-E-A-F-NH₂ 14Ac-E-W-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH₂ 15Ac-E-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-F-F-NH₂ 16Ac-E-W-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-A-F-NH₂ 17Ac-E-W-L-K-A-F-Y-D-K-V-F-E-K-L-K-E-F-F-NH₂ 18Ac-E-W-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-F-F-NH₂ 19Ac-E-W-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-NH₂ 20        AC-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH₂ 21        Ac-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH₂ 22        Ac-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH₂ 23        Ac-A-F-Y-D-K-F-F-E-K-F-K-E-F-F-NH₂ 24        Ac-A-F-Y-D-K-F-F-E-K-F-K-E-F-F-NH₂ 25        Ac-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH₂ 26        Ac-A-F-Y-D-K-V-A-E-K-L-K-E-F-F-NH₂ 27        Ac-A-F-Y-D-K-V-F-E-K-F-K-E-A-F-NH₂ 28        Ac-A-F-Y-D-K-V-F-E-K-L-K-E-F-F-NH₂ 29        Ac-A-F-Y-D-K-V-A-E-K-F-K-E-F-F-NH₂ 30        Ac-K-A-F-Y-D-K-V-F-E-K-F-K-E-F-NH₂ 31        Ac-L-F-Y-E-K-V-L-E-K-F-K-E-A-F-NH₂ 32        Ac-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH₂ 33        Ac-A-F-Y-D-K-V-A-E-K-L-K-E-F-F-NH₂ 34        Ac-A-F-Y-D-K-V-F-E-K-F-K-E-A-F-NH₂ 35        Ac-A-F-Y-D-K-V-F-E-K-L-K-E-F-F-NH₂ 36        Ac-A-F-Y-D-K-V-A-E-K-F-K-E-F-F-NH₂ 37        Ac-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-NH₂ 38Ac-D-W-L-K-A-L-Y-D-K-V-A-E-K-L-K-E-A-L-NH₂ 39Ac-D-W-F-K-A-F-Y-E-K-V-A-E-K-L-K-E-F-F-NH₂ 40Ac-D-W-F-K-A-F-Y-E-K-F-F-E-K-F-K-E-F-F-NH₂ 41Ac-E-W-L-K-A-L-Y-E-K-V-A-E-K-L-K-E-A-L-NH₂ 42Ac-E-W-L-K-A-F-Y-E-K-V-A-E-K-L-K-E-A-F-NH₂ 43Ac-E-W-F-K-A-F-Y-E-K-V-A-E-K-L-K-E-F-F-NH₂ 44Ac-E-W-L-K-A-F-Y-E-K-V-F-E-K-F-K-E-F-F-NH₂ 45Ac-E-W-L-K-A-F-Y-E-K-F-F-E-K-F-K-E-F-F-NH₂ 46Ac-E-W-F-K-A-F-Y-E-K-F-F-E-K-F-K-E-F-F-NH₂ 47Ac-D-F-L-K-A-W-Y-D-K-V-A-E-K-L-K-E-A-W-NH₂ 48Ac-E-F-L-K-A-W-Y-E-K-V-A-E-K-L-K-E-A-W-NH₂ 49Ac-D-F-W-K-A-W-Y-D-K-V-A-E-K-L-K-E-W-W-NH₂ 50Ac-E-F-W-K-A-W-Y-E-K-V-A-E-K-L-K-E-W-W-NH₂ 51Ac-D-K-L-K-A-F-Y-D-K-V-F-E-W-A-K-E-A-F-NH₂ 52Ac-D-K-W-K-A-V-Y-D-K-F-A-E-A-F-K-E-F-L-NH₂ 53Ac-E-K-L-K-A-F-Y-E-K-V-F-E-W-A-K-E-A-F-NH₂ 54Ac-E-K-W-K-A-V-Y-E-K-F-A-E-A-F-K-E-F-L-NH₂ 55Ac-D-W-L-K-A-F-V-D-K-F-A-E-K-F-K-E-A-Y-NH₂ 56Ac-E-K-W-K-A-V-Y-E-K-F-A-E-A-F-K-E-F-L-NH₂ 57Ac-D-W-L-K-A-F-V-Y-D-K-V-F-K-L-K-E-F-F-NH₂ 58Ac-E-W-L-K-A-F-V-Y-E-K-V-F-K-L-K-E-F-F-NH₂ 59Ac-D-W-L-R-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH₂ 60Ac-E-W-L-R-A-F-Y-E-K-V-A-E-K-L-K-E-A-F-NH₂ 61Ac-D-W-L-K-A-F-Y-D-R-V-A-E-K-L-K-E-A-F-NH₂ 62Ac-E-W-L-K-A-F-Y-E-R-V-A-E-K-L-K-E-A-F-NH₂ 63Ac-D-W-L-K-A-F-Y-D-K-V-A-E-R-L-K-E-A-F-NH₂ 64Ac-E-W-L-K-A-F-Y-E-K-V-A-E-R-L-K-E-A-F-NH₂ 65Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-L-R-E-A-F-NH₂ 66Ac-E-W-L-K-A-F-Y-E-K-V-A-E-K-L-R-E-A-F-NH₂ 67Ac-D-W-L-K-A-F-Y-D-R-V-A-E-R-L-K-E-A-F-NH₂ 68Ac-E-W-L-K-A-F-Y-E-R-V-A-E-R-L-K-E-A-F-NH₂ 69Ac-D-W-L-R-A-F-Y-D-K-V-A-E-K-L-R-E-A-F-NH₂ 70Ac-E-W-L-R-A-F-Y-E-K-V-A-E-K-L-R-E-A-F-NH₂ 71Ac-D-W-L-R-A-F-Y-D-R-V-A-E-K-L-K-E-A-F-NH₂ 72Ac-E-W-L-R-A-F-Y-E-R-V-A-E-K-L-K-E-A-F-NH₂ 73Ac-D-W-L-K-A-F-Y-D-K-V-A-E-R-L-R-E-A-F-NH₂ 74Ac-E-W-L-K-A-F-Y-E-K-V-A-E-R-L-R-E-A-F-NH₂ 75Ac-D-W-L-R-A-F-Y-D-K-V-A-E-R-L-K-E-A-F-NH₂ 76Ac-E-W-L-R-A-F-Y-E-K-V-A-E-R-L-K-E-A-F-NH₂ 77D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F- P -D-W- 78L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-F-F- P-D-W- 79 L-K-A-F-Y-D-K-V-A-E-K-L-K-E-F-FD-W-F-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F- P -D-W- 80F-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F D-K-L-K-A-F-Y-D-K-V-F-E-W-A-K-E-A-F- P-D-K- 81 L-K-A-F-Y-D-K-V-F-E-W-L-K-E-A-FD-K-W-K-A-V-Y-D-K-F-A-E-A-F-K-E-F-L- P -D-K- 82W-K-A-V-Y-D-K-F-A-E-A-F-K-E-F-L D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F- P-D-W- 83 F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-FD-W-L-K-A-F-V-Y-D-K-V-F-K-L-K-E-F-F- P -D-W- 84L-K-A-F-V-Y-D-K-V-F-K-L-K-E-F-F D-W-L-K-A-F-Y-D-K-F-A-E-K-F-K-E-F-F- P-D-W- 85 L-K-A-F-Y-D-K-F-A-E-K-F-K-E-F-F Ac-E-W-F-K-A-F-Y-E-K-V-A-E-K-F-K-E-A-F-NH₂ 86 Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-NH₂ 87 Ac-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-NH₂ 88 Ac-F-K-A-F-Y-E-K-V-A-E-K-F-K-E-NH₂ 89NMA-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-NH₂ 90NMA-F-K-A-F-Y-E-K-V-A-E-K-F-K-E-NH₂ 91NMA-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH₂ 92NMA-E-W-F-K-A-F-Y-E-K-V-A-E-K-F-K-E-A-F-NH₂ 93NMA-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH₂ 94NMA-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-NH₂ 95Ac-D-W-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-NH₂ 96NMA-D-W-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-NH₂ Ac-E-W-L-K-A-F-Y-E-K-V-F-E-K-F-K-E-F-F-NH₂ 97NMA-E-W-L-K-A-F-Y-E-K-V-F-E-K-F-K-E-F-F-NH₂ Ac-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-NH₂ 98NMA-A-F-Y-D-K-V-F-E-K-F-K-E-F-F-NH₂  Ac-A-F-Y-E-K-V-F-E-K-F-K-E-F-F-NH₂99 NMA-A-F-Y-E-K-V-F-E-K-F-K-E-F-F-NH₂ Ac-D-W-L-K-A-F-Y-D-K-V-F-E-K-F-NH₂ 100NMA-D-W-L-K-A-F-Y-D-K-V-F-E-K-F-NH₂  Ac-E-W-L-K-A-F-Y-E-K-V-F-E-K-F-NH₂101 NMA-E-W-L-K-A-F-Y-E-K-V-F-E-K-F-NH₂ Ac-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-NH₂ 102NMA-L-K-A-F-Y-D-K-V-F-E-K-F-K-E-NH₂  Ac-L-K-A-F-Y-E-K-V-F-E-K-F-K-E-NH₂103 NMA-L-K-A-F-Y-E-K-V-F-E-K-F-K-E-NH₂ ¹Linkers are underlined. NMA isN-Methyl Anthranilyl.

In certain preferred embodiments, the peptides include variations of 4F((SEQ ID NO:5 in Table 1, also known as L-4F, where all residues are Lform amino acids) or D-4F where one or more residues are D form aminoacids). In any of the peptides described herein, the C-terminus, and/orN-terminus, and/or internal residues can be blocked with one or moreblocking groups as described herein.

While various peptides of Table 1, are illustrated with an acetyl groupor an N-methylanthranilyl group protecting the amino terminus and anamide group protecting the carboxyl terminus, any of these protectinggroups may be eliminated and/or substituted with another protectinggroup as described herein. In particularly preferred embodiments, thepeptides comprise one or more D-form amino acids as described herein. Incertain embodiments, every amino acid (e.g., every enantiomeric aminoacid) of the peptides of Table 1 is a D-form amino acid.

It is also noted that Table 1 is not fully inclusive. Using theteachings provided herein, other suitable class A amphipathic helicalpeptides can routinely be produced (e.g., by conservative orsemi-conservative substitutions (e.g., D replaced by E), extensions,deletions, and the like). Thus, for example, one embodiment utilizestruncations of any one or more of peptides shown herein (e.g., peptidesidentified by SEQ ID Nos:2-20 and 39—in Table 1). Thus, for example, SEQID NO:21 illustrates a peptide comprising 14 amino acids from theC-terminus of 18A comprising one or more D amino acids, while SEQ IDNOS:22-38 illustrate other truncations.

Longer peptides are also suitable. Such longer peptides may entirelyform a class A amphipathic helix, or the class A amphipathic helix(helices) can form one or more domains of the peptide. In addition, thisinvention contemplates multimeric versions of the peptides (e.g.,concatamers). Thus, for example, the peptides illustrated herein can becoupled together (directly or through a linker (e.g., a carbon linker,or one or more amino acids) with one or more intervening amino acids).Illustrative polymeric peptides include 18A-Pro-18A and the peptides ofSEQ ID NOs:78-85, in certain embodiments comprising one or more D aminoacids, more preferably with every amino acid a D amino acid as describedherein and/or having one or both termini protected.

It will also be appreciated that, in addition to the peptide sequencesexpressly illustrated herein, this invention also contemplates retro andretro-inverso forms of each of these peptides. In retro forms, thedirection of the sequence is reversed. In inverse forms, the chiralityof the constituent amino acids is reversed (i.e., L form amino acidsbecome D form amino acids and D form amino acids become L form aminoacids). In the retro-inverso form, both the order and the chirality ofthe amino acids is reversed. Thus, for example, a retro form of the D4Fpeptide (DWFKAFYDKVAEKFKEAF, SEQ ID NO:5), where the amino terminus isat the aspartate (D) and the carboxyl terminus is at the phenylalanine(F), has the same sequence, but the amino terminus is at thephenylalanine and the carobxy terminus is at the aspartate (i.e.,FAEKFKEAVKDYFAKFWD, SEQ ID NO: 444). Where the D4F peptide comprises allD amino acids, the restro-inverso form will have the sequence shownabove (SEQ ID NO:444) and comprise all L form amino acids. Thus, forexample, 4F and Rev-4F are mirror images of each other with identicalsegregation of the polar and nonpolar faces with the positively chargedresidues residing at the polar-nonpolar interface and the negativelycharged residues residing at the center of the polar face. These mirrorimages of the same polymer of amino acids are identical in terms of thesegregation of the polar and nonpolar faces with the positively chargedresidues residing at the polar-nonpolar interface and the negativelycharged residues residing at the center of the polar face. For adiscussion of retro and retro-inverso peptides (see, e.g., Chorev andGoodman, (1995) TibTech, 13: 439-445).

Where reference is made to a sequence and orientation is not expresslyindicated, the sequence can be viewed as representing the amino acidsequence in the amino to carboxyl orientation, the retro form (i.e., theamino acid sequence in the carboxyl to amino orientation), the retroform where L amino acids are replaced with D amino acids or D aminoacids are replaced with L amino acids, and the retro-inverso form whereboth the order is reversed and the amino acid chirality is reversed.

It will also be appreciated that, in addition to the peptide sequencesexpressly illustrated herein, this invention also contemplates circularpermutations (CP) of such peptides and/or circular permutations of theretro-, inverso-, or retroinverso forms of such peptides. A circularpermutation of a peptide is a peptide that has an amino acid sequenceidentical to that produced by joining the amino and carboxyl termini ofthe original peptide and opening the circular peptide thus formed toform new amino and carboxyl termini.

B) Other Class a Amphipathic Helical Peptide Mimetics of Apoa-I HavingAromatic or Aliphatic Residues in the Non-Polar Face.

In certain embodiments, this invention also provides modified class Aamphipathic helix peptides. Certain preferred peptides incorporate oneor more aromatic residues at the center of the nonpolar face, e.g.,3F^(Cπ), (as present in 4F), or with one or more aliphatic residues atthe center of the nonpolar face, e.g., 3F^(1π), see, e.g., Table 2.Without being bound to a particular theory, we believe the centralaromatic residues on the nonpolar face of the peptide 3F^(Cπ), due tothe presence of T electrons at the center of the nonpolar face, allowwater molecules to penetrate near the hydrophobic lipid alkyl chains ofthe peptide-lipid complex, which in turn would enable the entry ofreactive oxygen species (such as lipid hydroperoxides) shielding themfrom the cell surface. Similarly, we also believe the peptides withaliphatic residues at the center of the nonpolar face, e.g., 3F^(1π),will act similarly but not quite as effectively as 3F^(Cπ).

Preferred peptides will convert pro-inflammatory HDL toanti-inflammatory HDL or make anti-inflammatory HDL moreanti-inflammatory, and/or decrease LDL-induced monocyte chemotacticactivity generated by artery wall cells equal to or greater than D4F orother peptides shown in Table 1.

TABLE 2 Examples of certain preferred peptides. Name Sequence SEQ ID NO(3F^(Cπ)) Ac-DKWKAVYDKFAEAFKEFL-NH₂ 104 (3F^(Iπ))Ac-DKLKAFYDKVFEWAKEAF-NH₂ 105

C) Smaller Peptides.

It was also a surprising discovery that certain small peptidesconsisting of a minimum of three amino acids preferentially (but notnecessarily) with one or more of the amino acids being theD-stereoisomer of the amino acid, and possessing hydrophobic domains topermit lipid protein interactions, and hydrophilic domains to permit adegree of water solubility also possess significant anti-inflammatoryproperties and are useful in treating one or more of the pathologiesdescribed herein. The “small peptides” typically range in length from 2amino acids to about 15 amino acids, more preferably from about 3 aminoacids to about 10 or 11 amino acids, and most preferably from about 4 toabout 8 or 10 amino acids. In various embodiments the peptides aretypically characterized by having hydrophobic terminal amino acids orterminal amino acids rendered hydrophobic by the attachment of one ormore hydrophobic “protecting” groups. Various “small peptides” aredescribed in copending applications U.S. Ser. No. 10/649,378, filed Aug.26, 2003, and in U.S. Ser. No. 10/913,800, filed on Aug. 6, 2004, and inPCT Application PCT/US2004/026288.

In certain embodiments, the peptides can be characterized by Formula I,below:

X¹-X²-X³ _(n)-X⁴  I

where, n is 0 or 1, X¹ is a hydrophobic amino acid and/or bears ahydrophobic protecting group, X⁴ is a hydrophobic amino acid and/orbears a hydrophobic protecting group; and when n is 0 X² is an acidic ora basic amino acid; when n is 1: X² and X³ are independently an acidicamino acid, a basic amino acid, an aliphatic amino acid, or an aromaticamino acid such that when X² is an acidic amino acid; X³ is a basicamino acid, an aliphatic amino acid, or an aromatic amino acid; when X²is a basic amino acid; X³ is an acidic amino acid, an aliphatic aminoacid, or an aromatic amino acid; and when X² is an aliphatic or aromaticamino acid, X³ is an acidic amino acid, or a basic amino acid.

Longer peptides (e.g., up to 10, 11, or 15 amino acids) are alsocontemplated within the scope of this invention. Typically where theshorter peptides (e.g., peptides according to formula I) arecharacterized by an acidic, basic, aliphatic, or aromatic amino acid,the longer peptides are characterized by acidic, basic, aliphatic, oraromatic domains comprising two or more amino acids of that type.

1) Functional Properties of Active Small Peptides.

It was a surprising finding of this invention that a number of physicalproperties predict the ability of small peptides (e.g., less than 10amino acids, preferably less than 8 amino acids, more preferably fromabout 3 to about 5 or 6 amino acids) of this invention to render HDLmore anti-inflammatory and to mitigate atherosclerosis and/or otherpathologies characterized by an inflammatory response in a mammal. Thephysical properties include high solubility in ethyl acetate (e.g.,greater than about 4 mg/mL), and solubility in aqueous buffer at pH 7.0.Upon contacting phospholipids such as1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC), in an aqueousenvironment, the particularly effective small peptides induce orparticipate in the formation of particles with a diameter ofapproximately 7.5 nm (±0.1 nm), and/or induce or participate in theformation of stacked bilayers with a bilayer dimension on the order of3.4 to 4.1 nm with spacing between the bilayers in the stack ofapproximately 2 nm, and/or also induce or participate in the formationof vesicular structures of approximately 38 nm). In certain preferredembodiments, the small peptides have a molecular weight of less thanabout 900 Da.

Thus, in certain embodiments, this invention contemplates small peptidesthat ameliorate one or more symptoms of an indication/pathologydescribed herein, e.g., an inflammatory condition, where the peptide(s):ranges in length from about 3 to about 8 amino acids, preferably fromabout 3 to about 6, or 7 amino acids, and more preferably from about 3to about 5 amino acids; are soluble in ethyl acetate at a concentrationgreater than about 4 mg/mL; are soluble in aqueous buffer at pH 7.0;when contacted with a phospholipid in an aqueous environment, formparticles with a diameter of approximately 7.5 nm and/or form stackedbilayers with a bilayer dimension on the order of 3.4 to 4.1 nm withspacing between the bilayers in the stack of approximately 2 nm; have amolecular weight less than about 900 daltons; convert pro-inflammatoryHDL to anti-inflammatory HDL or make anti-inflammatory HDL moreanti-inflammatory; and do not have the amino acid sequenceLys-Arg-Asp-Ser (SEQ ID NO:235), especially in which Lys-Arg-Asp and Serare all L amino acids. In certain embodiments, these small peptidesprotect a phospholipid against oxidation by an oxidizing agent.

While these small peptides need not be so limited, in certainembodiments, these small peptides can include the small peptidesdescribed below.

2) Tripeptide.

It was discovered that certain tripeptide (3 amino acid peptides) can besynthesized that show desirable properties as described herein (e.g.,the ability to convert pro-inflammatory HDL to anti-inflammatory HDL,the ability to decrease LDL-induced monocyte chemotactic activitygenerated by artery wall cells, the ability to increase pre-beta HDL,etc.). In certain embodiments, the peptides are characterized by formulaI, wherein N is zero, shown below as Formula II:

X¹-X²-X⁴  II

where the end amino acids (X¹ and X⁴) are hydrophobic either because ofa hydrophobic side chain or because the side chain or the C and/or Nterminus is blocked with one or more hydrophobic protecting group(s)(e.g., the N-terminus is blocked with Boc-, Fmoc-, nicotinyl-, etc., andthe C-terminus blocked with (tBu)-OtBu, etc.). In certain embodiments,the X² amino acid is either acidic (e.g., aspartic acid, glutamic acid,etc.) or basic (e.g., histidine, arginine, lysine, etc.). The peptidecan be all L-amino acids or include one or more or all D-amino acids.

Certain preferred tripeptide of this invention include, but are notlimited to the peptides shown in Table 3.

TABLE 3 Examples of certain preferred tripeptides bearing hydrophobicblocking groups and acidic, basic, or histidine central amino acids. X¹X² X³ X⁴ SEQ ID NO Boc-Lys(εBoc) Arg Ser(tBu)-OtBu 106 Boc-Lys(εBoc) ArgThr(tBu)-OtBu 107 Boc-Trp Arg Ile-OtBu 108 Boc-Trp Arg Leu-OtBu 109Boc-Phe Arg Ile-OtBu 110 Boc-Phe Arg Leu-OtBu 111 Boc-Lys(εBoc) GluSer(tBu)-OtBu 112 Boc-Lys(εBoc) Glu Thr(tBu)-OtBu 113 Boc-Lys(εBoc) AspSer(tBu)-OtBu 114 Boc-Lys(εBoc) Asp Thr(tBu)-OtBu 115 Boc-Lys(εBoc) ArgSer(tBu)-OtBu 116 Boc-Lys(εBoc) Arg Thr(tBu)-OtBu 117 Boc-Leu GluSer(tBu)-OtBu 118 Boc-Leu Glu Thr(tBu)-OtBu 119 Fmoc-Trp ArgSer(tBu)-OtBu 120 Fmoc-Trp Asp Ser(tBu)-OtBu 121 Fmoc-Trp GluSer(tBu)-OtBu 122 Fmoc-Trp Arg Ser(tBu)-OtBu 123 Boc-Lys(εBoc) GluLeu-OtBu 124 Fmoc-Leu Arg Ser(tBu)-OtBu 125 Fmoc-Leu Asp Ser(tBu)-OtBu126 Fmoc-Leu Glu Ser(tBu)-OtBu 127 Fmoc-Leu Arg Ser(tBu)-OtBu 128Fmoc-Leu Arg Thr(tBu)-OtBu 129 Boc-Glu Asp Tyr(tBu)-OtBu 130Fmoc-Lys(εFmoc) Arg Ser(tBu)-OtBu 131 Fmoc-Trp Arg Ile-OtBu 132 Fmoc-TrpArg Leu-OtBu 133 Fmoc-Phe Arg Ile-OtBu 134 Fmoc-Phe Arg Leu-OtBu 135Boc-Trp Arg Phe-OtBu 136 Boc-Trp Arg Tyr-OtBu 137 Fmoc-Trp Arg Phe-OtBu138 Fmoc-Trp Arg Tyr-OtBu 139 Boc-Orn(δBoc) Arg Ser(tBu)-OtBu 140Nicotinyl Lys(εBoc) Arg Ser(tBu)-OtBu 141 Nicotinyl Lys(εBoc) ArgThr(tBu)-OtBu 142 Fmoc-Leu Asp Thr(tBu)-OtBu 143 Fmoc-Leu GluThr(tBu)-OtBu 144 Fmoc-Leu Arg Thr(tBu)-OtBu 145 Fmoc-norLeu ArgSer(tBu)-OtBu 146 Fmoc-norLeu Asp Ser(tBu)-OtBu 147 Fmoc-norLeu GluSer(tBu)-OtBu 148 Fmoc-Lys(εBoc) Arg Ser(tBu)-OtBu 149 Fmoc-Lys(εBoc)Arg Thr(tBu)-OtBu 150 Fmoc-Lys(εBoc) Glu Ser(tBu)-OtBu 151Fmoc-Lys(εBoc) Glu Thr(tBu)-OtBu 152 Fmoc-Lys(εBoc) Asp Ser(tBu)-OtBu153 Fmoc-Lys(εBoc) Asp Thr(tBu)-OtBu 154 Fmoc-Lys(εBoc) Glu Leu-OtBu 155Fmoc-Lys(εBoc) Arg Leu-OtBu 156 Fmoc-LysεFmoc) Arg Thr(tBu)-OtBu 157Fmoc- LysεFmoc) Glu Ser(tBu)-OtBu 158 Fmoc- LysεFmoc) Glu Thr(tBu)-OtBu159 Fmoc- LysεFmoc) Asp Ser(tBu)-OtBu 160 Fmoc- LysεFmoc) AspThr(tBu)-OtBu 161 Fmoc- LysεFmoc) Arg Ser(tBu)-OtBu 162 Fmoc- LysεFmoc))Glu Leu-OtBu 163 Boc-LysεFmoc) Asp Ser(tBu)-OtBu 164 Boc-LysεFmoc) AspThr(tBu)-OtBu 165 Boc-LysεFmoc) Arg Thr(tBu)-OtBu 166 Boc-LysεFmoc) GluLeu-OtBu 167 Boc-Orn(δFmoc) Glu Ser(tBu)-OtBu 168 Boc-Orn(δFmoc) AspSer(tBu)-OtBu 169 Boc-Orn(δFmoc) Asp Thr(tBu)-OtBu 170 Boc-Orn(δFmoc)Arg Thr(tBu)-OtBu 171 Boc-Orn(δFmoc) Glu Thr(tBu)-OtBu 172 Fmoc-Trp AspIle-OtBu 173 Fmoc-Trp Arg Ile-OtBu 174 Fmoc-Trp Glu Ile-OtBu 175Fmoc-Trp Asp Leu-OtBu 176 Fmoc-Trp Glu Leu-OtBu 177 Fmoc-Phe AspIle-OtBu 178 Fmoc-Phe Asp Leu-OtBu 179 Fmoc-Phe Glu Leu-OtBu 180Fmoc-Trp Arg Phe-OtBu 181 Fmoc-Trp Glu Phe-OtBu 182 Fmoc-Trp AspPhe-OtBu 183 Fmoc-Trp Asp Tyr-OtBu 184 Fmoc-Trp Arg Tyr-OtBu 185Fmoc-Trp Glu Tyr-OtBu 186 Fmoc-Trp Arg Thr(tBu)-OtBu 187 Fmoc-Trp AspThr(tBu)-OtBu 188 Fmoc-Trp Glu Thr(tBu)-OtBu 189 Boc-Phe Arg norLeu-OtBu190 Boc-Phe Glu norLeu-OtBu 191 Fmoc-Phe Asp norLeu-OtBu 192 Boc-Glu HisTyr(tBu)-OtBu 193 Boc-Leu His Ser(tBu)-OtBu 194 Boc-Leu HisThr(tBu)-OtBu 195 Boc-Lys(εBoc) His Ser(tBu)-OtBu 196 Boc-Lys(εBoc) HisThr(tBu)-OtBu 197 Boc-Lys(εBoc) His Leu-OtBu 198 Boc-LysεFmoc) HisSer(tBu)-OtBu 199 Boc-LysεFmoc) His Thr(tBu)-OtBu 200 Boc-LysεFmoc) HisLeu-OtBu 201 Boc-Orn(δBoc) His Ser(tBu)-OtBu 202 Boc-Orn(δFmoc) HisThr(tBu)-OtBu 203 Boc-Phe His Ile-OtBu 204 Boc-Phe His Leu-OtBu 205Boc-Phe His norLeu-OtBu 206 Boc-Phe Lys Leu-OtBu 207 Boc-Trp HisIle-OtBu 208 Boc-Trp His Leu-OtBu 209 Boc-Trp His Phe-OtBu 210 Boc-TrpHis Tyr-OtBu 211 Boc-Phe Lys Leu-OtBu 212 Fmoc-LysεFmoc) HisSer(tBu)-OtBu 213 Fmoc-LysεFmoc) His Thr(tBu)-OtBu 214 Fmoc-LysεFmoc)His Leu-OtBu 215 Fmoc-Leu His Ser(tBu)-OtBu 216 Fmoc-Leu HisThr(tBu)-OtBu 217 Fmoc-Lys(εBoc) His Ser(tBu)-OtBu 218 Fmoc-Lys(εBoc)His Thr(tBu)-OtBu 219 Fmoc-Lys(εBoc) His Leu-OtBu 220 Fmoc-LysεFmoc) HisSer(tBu)-OtBu 221 Fmoc-LysεFmoc) His Thr(tBu)-OtBu 222 Fmoc-norLeu HisSer(tBu)-OtBu 223 Fmoc-Phe His Ile-OtBu 224 Fmoc-Phe His Leu-OtBu 225Fmoc-Phe His norLeu-OtBu 226 Fmoc-Trp His Ser(tBu)-OtBu 227 Fmoc-Trp HisIle-OtBu 228 Fmoc-Trp His Leu-OtBu 229 Fmoc-Trp His Phe-OtBu 230Fmoc-Trp His Tyr-OtBu 231 Fmoc-Trp His Thr(tBu)-OtBu 232 NicotinylLys(εBoc) His Ser(tBu)-OtBu 233 Nicotinyl Lys(εBoc) His Thr(tBu)-OtBu234

While the peptides of Table 3 are illustrated with particular protectinggroups, it is noted that these groups may be substituted with otherprotecting groups as described herein and/or one or more of the shownprotecting group can be eliminated.

3) Small Peptides with Central Acidic and Basic Amino Acids.

In certain embodiments, the peptides of this invention range from fouramino acids to about ten amino acids. The terminal amino acids aretypically hydrophobic either because of a hydrophobic side chain orbecause the terminal amino acids bear one or more hydrophobic protectinggroups end amino acids (X¹ and X⁴) are hydrophobic either because of ahydrophobic side chain or because the side chain or the C and/or Nterminus is blocked with one or more hydrophobic protecting group(s)(e.g., the N-terminus is blocked with Boc-, Fmoc-, Nicotinyl-, etc., andthe C-terminus blocked with (tBu)-OtBu, etc.). Typically, the centralportion of the peptide comprises a basic amino acid and an acidic aminoacid (e.g., in a 4 mer) or a basic domain and/or an acidic domain in alonger molecule.

These four-mers can be represented by Formula I in which X¹ and X⁴ arehydrophobic and/or bear hydrophobic protecting group(s) as describedherein and X² is acidic while X³ is basic or X² is basic while X³ isacidic. The peptide can be all L-amino acids or include one or more orall D-amino acids.

Certain preferred of this invention include, but are not limited to thepeptides shown in Table 4.

TABLE 4 Illustrative examples of small peptides with central acidic andbasic amino acids. X¹ X² X³ X⁴ SEQ ID NO Boc-Lys(εBoc) Arg AspSer(tBu)-OtBu 235 Boc-Lys(εBoc) Arg Asp Thr(tBu)-OtBu 236 Boc-Trp ArgAsp Ile-OtBu 237 Boc-Trp Arg Asp Leu-OtBu 238 Boc-Phe Arg Asp Leu-OtBu239 Boc-Phe Arg Asp Ile-OtBu 240 Boc-Phe Arg Asp norLeu-OtBu 241 Boc-PheArg Glu norLeu-OtBu 242 Boc-Phe Arg Glu Ile-OtBu 243 Boc-Phe Asp ArgIle-OtBu 244 Boc-Phe Glu Arg Ile-OtBu 245 Boc-Phe Asp Arg Leu-OtBu 246Boc-Phe Arg Glu Leu-OtBu 247 Boc-Phe Glu Arg Leu-OtBu 248 Boc-Phe AspArg norLeu-OtBu 249 Boc-Phe Glu Arg norLeu-OtBu 250 Boc-Lys(εBoc) GluArg Ser(tBu)-OtBu 251 Boc-Lys(εBoc) Glu Arg Thr(tBu)-OtBu 252Boc-Lys(εBoc) Asp Arg Ser(tBu)-OtBu 253 Boc-Lys(εBoc) Asp ArgThr(tBu)-OtBu 254 Boc-Lys(εBoc) Arg Glu Ser(tBu)-OtBu 255 Boc-Lys(εBoc)Arg Glu Thr(tBu)-OtBu 256 Boc-Leu Glu Arg Ser(tBu)-OtBu 257 Boc-Leu GluArg Thr(tBu)-OtBu 258 Fmoc-Trp Arg Asp Ser(tBu)-OtBu 259 Fmoc-Trp AspArg Ser(tBu)-OtBu 260 Fmoc-Trp Glu Arg Ser(tBu)-OtBu 261 Fmoc-Trp ArgGlu Ser(tBu)-OtBu 262 Boc-Lys(εBoc) Glu Arg Leu-OtBu 263 Fmoc-Leu ArgAsp Ser(tBu)-OtBu 264 Fmoc-Leu Asp Arg Ser(tBu)-OtBu 265 Fmoc-Leu GluArg Ser(tBu)-OtBu 266 Fmoc-Leu Arg Glu Ser(tBu)-OtBu 267 Fmoc-Leu ArgAsp Thr(tBu)-OtBu 268 Boc-Glu Asp Arg Tyr(tBu)-OtBu 269 Fmoc-LysεFmoc)Arg Asp Ser(tBu)-OtBu 270 Fmoc-Trp Arg Asp Ile-OtBu 271 Fmoc-Trp Arg AspLeu-OtBu 272 Fmoc-Phe Arg Asp Ile-OtBu 273 Fmoc-Phe Arg Asp Leu-OtBu 274Boc-Trp Arg Asp Phe-OtBu 275 Boc-Trp Arg Asp Tyr-OtBu 276 Fmoc-Trp ArgAsp Phe-OtBu 277 Fmoc-Trp Arg Asp Tyr-OtBu 278 Boc-Orn(δBoc) Arg GluSer(tBu)-OtBu 279 Nicotinyl Lys(εBoc) Arg Asp Ser(tBu)-OtBu 280Nicotinyl Lys(εBoc) Arg Asp Thr(tBu)-OtBu 281 Fmoc-Leu Asp ArgThr(tBu)-OtBu 282 Fmoc-Leu Glu Arg Thr(tBu)-OtBu 283 Fmoc-Leu Arg GluThr(tBu)-OtBu 284 Fmoc-norLeu Arg Asp Ser(tBu)-OtBu 285 Fmoc-norLeu AspArg Ser(tBu)-OtBu 286 Fmoc-norLeu Glu Arg Ser(tBu)-OtBu 287 Fmoc-norLeuArg Glu Ser(tBu)-OtBu 288 Fmoc-Lys(εBoc) Arg Asp Ser(tBu)-OtBu 289Fmoc-Lys(εBoc) Arg Asp Thr(tBu)-OtBu 290 Fmoc-Lys(εBoc) Glu ArgSer(tBu)-OtBu 291 Fmoc-Lys(εBoc) Glu Arg Thr(tBu)-OtBu 292Fmoc-Lys(εBoc) Asp Arg Ser(tBu)-OtBu 293 Fmoc-Lys(εBoc) Asp ArgThr(tBu)-OtBu 294 Fmoc-Lys(εBoc) Arg Glu Ser(tBu)-OtBu 295Fmoc-Lys(εBoc) Arg Glu Thr(tBu)-OtBu 296 Fmoc-Lys(εBoc) Glu Arg Leu-OtBu297 Fmoc-Lys(εBoc) Arg Glu Leu-OtBu 298 Fmoc-LysεFmoc) Arg AspThr(tBu)-OtBu 299 Fmoc-LysεFmoc) Glu Arg Ser(tBu)-OtBu 300Fmoc-LysεFmoc) Glu Arg Thr(tBu)-OtBu 301 Fmoc-LysεFmoc) Asp ArgSer(tBu)-OtBu 302 Fmoc-LysεFmoc) Asp Arg Thr(tBu)-OtBu 303Fmoc-LysεFmoc) Arg Glu Ser(tBu)-OtBu 304 Fmoc-LysεFmoc) Arg GluThr(tBu)-OtBu 305 Fmoc-LysεFmoc)) Glu Arg Leu-OtBu 306 Boc-LysεFmoc) ArgAsp Ser(tBu)-OtBu 307 Boc-LysεFmoc) Arg Asp Thr(tBu)-OtBu 308Boc-LysεFmoc) Glu Arg Ser(tBu)-OtBu 309 Boc-LysεFmoc) Glu ArgThr(tBu)-OtBu 310 Boc-LysεFmoc) Asp Arg Ser(tBu)-OtBu 311 Boc-LysεFmoc)Asp Arg Thr(tBu)-OtBu 312 Boc-LysεFmoc) Arg Glu Ser(tBu)-OtBu 313Boc-LysεFmoc) Arg Glu Thr(tBu)-OtBu 314 Boc-LysεFmoc) Glu Arg Leu-OtBu315 Boc-Orn(δFmoc) Arg Glu Ser(tBu)-OtBu 316 Boc-Orn(δFmoc) Glu ArgSer(tBu)-OtBu 317 Boc-Orn(δFmoc) Arg Asp Ser(tBu)-OtBu 318Boc-Orn(δFmoc) Asp Arg Ser(tBu)-OtBu 319 Boc-Orn(δFmoc) Asp ArgThr(tBu)-OtBu 320 Boc-Orn(δFmoc) Arg Asp Thr(tBu)-OtBu 321Boc-Orn(δFmoc) Glu Arg Thr(tBu)-OtBu 322 Boc-Orn(δFmoc) Arg GluThr(tBu)-OtBu 323 Fmoc-Trp Asp Arg Ile-OtBu 324 Fmoc-Trp Arg GluIle-OtBu 325 Fmoc-Trp Glu Arg Ile-OtBu 326 Fmoc-Trp Asp Arg Leu-OtBu 327Fmoc-Trp Arg Glu Leu-OtBu 328 Fmoc-Trp Glu Arg Leu-OtBu 329 Fmoc-Phe AspArg Ile-OtBu 330 Fmoc-Phe Arg Glu Ile-OtBu 331 Fmoc-Phe Glu Arg Ile-OtBu332 Fmoc-Phe Asp Arg Leu-OtBu 333 Fmoc-Phe Arg Glu Leu-OtBu 334 Fmoc-PheGlu Arg Leu-OtBu 335 Fmoc-Trp Arg Asp Phe-OtBu 336 Fmoc-Trp Arg GluPhe-OtBu 337 Fmoc-Trp Glu Arg Phe-OtBu 338 Fmoc-Trp Asp Arg Tyr-OtBu 339Fmoc-Trp Arg Glu Tyr-OtBu 340 Fmoc-Trp Glu Arg Tyr-OtBu 341 Fmoc-Trp ArgAsp Thr(tBu)-OtBu 342 Fmoc-Trp Asp Arg Thr(tBu)-OtBu 343 Fmoc-Trp ArgGlu Thr(tBu)-OtBu 344 Fmoc-Trp Glu Arg Thr(tBu)-OtBu 345 Fmoc-Phe ArgAsp norLeu-OtBu 346 Fmoc-Phe Arg Glu norLeu-OtBu 347 Boc-Phe Lys AspLeu-OtBu 348 Boc-Phe Asp Lys Leu-OtBu 349 Boc-Phe Lys Glu Leu-OtBu 350Boc-Phe Glu Lys Leu-OtBu 351 Boc-Phe Lys Asp Ile-OtBu 352 Boc-Phe AspLys Ile-OtBu 353 Boc-Phe Lys Glu Ile-OtBu 354 Boc-Phe Glu Lys Ile-OtBu355 Boc-Phe Lys Asp norLeu-OtBu 356 Boc-Phe Asp Lys norLeu-OtBu 357Boc-Phe Lys Glu norLeu-OtBu 358 Boc-Phe Glu Lys norLeu-OtBu 359 Boc-PheHis Asp Leu-OtBu 360 Boc-Phe Asp His Leu-OtBu 361 Boc-Phe His GluLeu-OtBu 362 Boc-Phe Glu His Leu-OtBu 363 Boc-Phe His Asp Ile-OtBu 364Boc-Phe Asp His Ile-OtBu 365 Boc-Phe His Glu Ile-OtBu 366 Boc-Phe GluHis Ile-OtBu 367 Boc-Phe His Asp norLeu-OtBu 368 Boc-Phe Asp HisnorLeu-OtBu 369 Boc-Phe His Glu norLeu-OtBu 370 Boc-Phe Glu HisnorLeu-OtBu 371 Boc-Lys(εBoc) Lys Asp Ser(tBu)-OtBu 372 Boc-Lys(εBoc)Asp Lys Ser(tBu)-OtBu 373 Boc-Lys(εBoc) Lys Glu Ser(tBu)-OtBu 374Boc-Lys(εBoc) Glu Lys Ser(tBu)-OtBu 375 Boc-Lys(εBoc) His AspSer(tBu)-OtBu 376 Boc-Lys(εBoc) Asp His Ser(tBu)-OtBu 377 Boc-Lys(εBoc)His Glu Ser(tBu)-OtBu 378 Boc-Lys(εBoc) Glu His Ser(tBu)-OtBu 379

While the peptides of Table 4 are illustrated with particular protectinggroups, it is noted that these groups may be substituted with otherprotecting groups as described herein and/or one or more of the shownprotecting group can be eliminated.

4) Small Peptides Having Either an Acidic or Basic Amino Acid in theCenter to Together with a Central Aliphatic Amino Acid.

In certain embodiments, the peptides of this invention range from fouramino acids to about ten amino acids. The terminal amino acids aretypically hydrophobic either because of a hydrophobic side chain orbecause the terminal amino acids bear one or more hydrophobic protectinggroups. End amino acids (X¹ and X⁴) are hydrophobic either because of ahydrophobic side chain or because the side chain or the C and/or Nterminus is blocked with one or more hydrophobic protecting group(s)(e.g., the N-terminus is blocked with Boc-, Fmoc-, Nicotinyl-, etc., andthe C-terminus blocked with (tBu)-OtBu, etc.). Typically, the centralportion of the peptide comprises a basic or acidic amino acid and analiphatic amino acid (e.g., in a 4 mer) or a basic domain or an acidicdomain and an aliphatic domain in a longer molecule.

These four-mers can be represented by Formula I in which X¹ and X⁴ arehydrophobic and/or bear hydrophobic protecting group(s) as describedherein and X² is acidic or basic while X³ is aliphatic or X² isaliphatic while X³ is acidic or basic. The peptide can be all L-aminoacids or include one, or more, or all D-amino acids.

Certain preferred peptides of this invention include, but are notlimited to the peptides shown in Table 5.

TABLE 5 Examples of certain prefeffed peptides having either an acidicor basic amino acid in the center together with a central aliphaticamino acid. X¹ X² X³ X⁴ SEQ ID NO Fmoc-Lys(εBoc) Leu Arg Ser(tBu)-OtBu380 Fmoc-Lys(εBoc) Arg Leu Ser(tBu)-OtBu 381 Fmoc-Lys(εBoc) Leu ArgThr(tBu)-OtBu 382 Fmoc-Lys(εBoc) Arg Leu Thr(tBu)-OtBu 383Fmoc-Lys(εBoc) Glu Leu Ser(tBu)-OtBu 384 Fmoc-Lys(εBoc) Leu GluSer(tBu)-OtBu 385 Fmoc-Lys(εBoc) Glu Leu Thr(tBu)-OtBu 386Fmoc-LysεFmoc) Leu Arg Ser(tBu)-OtBu 387 Fmoc-LysεFmoc) Leu ArgThr(tBu)-OtBu 388 Fmoc-LysεFmoc) Glu Leu Ser(tBu)-OtBu 389Fmoc-LysεFmoc) Glu Leu Thr(tBu)-OtBu 390 Boc-Lys(Fmoc) Glu IleThr(tBu)-OtBu 391 Boc-LysεFmoc) Leu Arg Ser(tBu)-OtBu 392 Boc-LysεFmoc)Leu Arg Thr(tBu)-OtBu 393 Boc-LysεFmoc) Glu Leu Ser(tBu)-OtBu 394Boc-LysεFmoc) Glu Leu Thr(tBu)-OtBu 395 Boc-Lys(εBoc) Leu ArgSer(tBu)-OtBu 396 Boc-Lys(εBoc) Arg Phe Thr(tBu)-OtBu 397 Boc-Lys(εBoc)Leu Arg Thr(tBu)-OtBu 398 Boc-Lys(εBoc) Glu Ile Thr(tBu) 399Boc-Lys(εBoc) Glu Val Thr(tBu) 400 Boc-Lys(εBoc) Glu Ala Thr(tBu) 401Boc-Lys(εBoc) Glu Gly Thr(tBu) 402 Boc-Lys(εBoc) Glu Leu Ser(tBu)-OtBu403 Boc-Lys(εBoc) Glu Leu Thr(tBu)-OtBu 404

While the peptides of Table 5 are illustrated with particular protectinggroups, it is noted that these groups may be substituted with otherprotecting groups as described herein and/or one or more of the shownprotecting group can be eliminated.

5) Small Peptides Having Either an Acidic or Basic Amino Acid in theCenter to Together with a Central Aromatic Amino Acid.

In certain embodiments, the “small” peptides of this invention rangefrom four amino acids to about ten amino acids. The terminal amino acidsare typically hydrophobic either because of a hydrophobic side chain orbecause the terminal amino acids bear one or more hydrophobic protectinggroups end amino acids (X¹ and X⁴) are hydrophobic either because of ahydrophobic side chain or because the side chain or the C and/or Nterminus is blocked with one or more hydrophobic protecting group(s)(e.g., the N-terminus is blocked with Boc-, Fmoc-, Nicotinyl-, etc., andthe C-terminus blocked with (tBu)-OtBu, etc.). Typically, the centralportion of the peptide comprises a basic or acidic amino acid and anaromatic amino acid (e.g., in a 4 mer) or a basic domain or an acidicdomain and an aromatic domain in a longer molecule.

These four-mers can be represented by Formula I in which X¹ and X⁴ arehydrophobic and/or bear hydrophobic protecting group(s) as describedherein and X² is acidic or basic while X³ is aromatic or X² is aromaticwhile X³ is acidic or basic. The peptide can be all L-amino acids orinclude one, or more, or all D-amino acids. Five-mers can be representedby a minor modification of Formula I in which X⁵ is inserted as shown inTable 6 and in which X⁵ is typically an aromatic amino acid. Certainpreferred peptides of this invention include, but are not limited to thepeptides shown in Table 6.

TABLE 6 Examples of certain preferred peptides having either an acidicor basic amino acid in the center together with a central aromatic aminoacid. SEQ ID X¹ X² X³ X⁵ X⁴ NO Fmoc-Lys(εBoc) Arg Trp Tyr(tBu)-OtBu 405Fmoc-Lys(εBoc) Trp Arg Tyr(tBu)-OtBu 406 Fmoc-Lys(εBoc) Arg Tyr Trp-OtBu407 Fmoc-Lys(εBoc) Tyr Arg Trp-OtBu 408 Fmoc-Lys(εBoc) Arg Tyr TrpThr(tBu)-OtBu 409 Fmoc-Lys(εBoc) Arg Tyr Thr(tBu)-OtBu 410Fmoc-Lys(εBoc) Arg Trp Thr(tBu)-OtBu 411 Fmoc-Lys(εFmoc) Arg TrpTyr(tBu)-OtBu 412 Fmoc-Lys(εFmoc) Arg Tyr Trp-OtBu 413 Fmoc-Lys(εFmoc)Arg Tyr Trp Thr(tBu)-OtBu 414 Fmoc-Lys(εFmoc) Arg Tyr Thr(tBu)-OtBu 415Fmoc-Lys(εFmoc) Arg Trp Thr(tBu)-OtBu 416 Boc-Lys(εFmoc) Arg TrpTyr(tBu)-OtBu 417 Boc-Lys(εFmoc) Arg Tyr Trp-OtBu 418 Boc-Lys(εFmoc) ArgTyr Trp Thr(tBu)-OtBu 419 Boc-Lys(εFmoc) Arg Tyr Thr(tBu)-OtBu 420Boc-Lys(εFmoc) Arg Trp Thr(tBu)-OtBu 421 Boc-Glu Lys(εFmoc) ArgTyr(tBu)-OtBu 422 Boc-Lys(εBoc) Arg Trp Tyr(tBu)-OtBu 423 Boc-Lys(εBoc)Arg Tyr Trp-OtBu 424 Boc-Lys(εBoc) Arg Tyr Trp Thr(tBu)-OtBu 425Boc-Lys(εBoc) Arg Tyr Thr(tBu)-OtBu 426 Boc-Lys(εBoc) Arg PheThr(tBu)-OtBu 427 Boc-Lys(εBoc) Arg Trp Thr(tBu)-OtBu 428

While the peptides of Table 6 are illustrated with particular protectinggroups, it is noted that these groups may be substituted with otherprotecting groups as described herein and/or one or more of the shownprotecting group can be eliminated.

6) Small Peptides Having Aromatic Amino Acids or Aromatic Amino AcidsSeparated by Histidine(s) at the Center.

In certain embodiments, the peptides of this invention are characterizedby π electrons that are exposed in the center of the molecule whichallow hydration of the particle and that allow the peptide particles totrap pro-inflammatory oxidized lipids such as fatty acid hydroperoxidesand phospholipids that contain an oxidation product of arachidonic acidat the sn-2 position.

In certain embodiments, these peptides consist of a minimum of 4 aminoacids and a maximum of about 10 amino acids, preferentially (but notnecessarily) with one or more of the amino acids being theD-stereoisomer of the amino acid, with the end amino acids beinghydrophobic either because of a hydrophobic side chain or because theterminal amino acid(s) bear one or more hydrophobic blocking group(s),(e.g., an N-terminus blocked with Boc-, Fmoc-, Nicotinyl-, and the like,and a C-terminus blocked with (tBu)-OtBu groups and the like). Insteadof having an acidic or basic amino acid in the center, these peptidesgenerally have an aromatic amino acid at the center or have aromaticamino acids separated by histidine in the center of the peptide.

Certain preferred peptides of this invention include, but are notlimited to the peptides shown in Table 7.

TABLE 7 Examples of peptides having aromatic amino acids in the centeror aromatic amino acids or aromatic domains separated by one or morehistidines. SEQ ID X¹ X² X³ X⁴ X⁵ NO Boc-Lys(εBoc) Phe Trp PheSer(tBu)-OtBu 429 Boc-Lys(εBoc) Phe Trp Phe Thr(tBu)-OtBu 430Boc-Lys(εBoc) Phe Tyr Phe Ser(tBu)-OtBu 431 Boc-Lys(εBoc) Phe Tyr PheThr(tBu)-OtBu 432 Boc-Lys(εBoc) Phe His Phe Ser(tBu)-OtBu 433Boc-Lys(εBoc) Phe His Phe Thr(tBu)-OtBu 434 Boc-Lys(εBoc) Val PhePhe-Tyr Ser(tBu)-OtBu 435 Nicotinyl-Lys(εBoc) Phe Trp Phe Ser(tBu)-OtBu436 Nicotinyl-Lys(εBoc) Phe Trp Phe Thr(tBu)-OtBu 437Nicotinyl-Lys(εBoc) Phe Tyr Phe Ser(tBu)-OtBu 438 Nicotinyl-Lys(εBoc)Phe Tyr Phe Thr(tBu)-OtBu 439 Nicotinyl-Lys(εBoc) Phe His PheSer(tBu)-OtBu 440 Nicotinyl-Lys(εBoc) Phe His Phe Thr(tBu)-OtBu 441Boc-Leu Phe Trp Phe Thr(tBu)-OtBu 442 Boc-Leu Phe Trp Phe Ser(tBu)-OtBu443

While the peptides of Table 7 are illustrated with particular protectinggroups, it is noted that these groups may be substituted with otherprotecting groups as described herein and/or one or more of the shownprotecting group can be eliminated.

7) Summary of Tripeptides and Tetrapeptides.

For the sake of clarity, a number of tripeptides and tetrapeptides ofthis invention are generally summarized below in Table 8.

TABLE 8 General structure of certain peptides of this invention. X¹ X²X³ X⁴ hydrophobic side chain Acidic or — hydrophobic side or hydrophobicBasic chain or protecting group(s) hydrophobic protecting group(s)hydrophobic side chain Basic Acidic hydrophobic side or hydrophobicchain or protecting group(s) hydrophobic protecting group(s) hydrophobicside chain Acidic Basic hydrophobic side or hydrophobic chain orprotecting group(s) hydrophobic protecting group(s) hydrophobic sidechain Acidic or Aliphatic hydrophobic side or hydrophobic Basic chain orprotecting group(s) hydrophobic protecting group(s) hydrophobic sidechain Aliphatic Acidic or hydrophobic side or hydrophobic Basic chain orprotecting group(s) hydrophobic protecting group(s) hydrophobic sidechain Acidic or Aromatic hydrophobic side or hydrophobic Basic chain orprotecting group(s) hydrophobic protecting group(s) hydrophobic sidechain Aromatic Acidic or hydrophobic side or hydrophobic Basic chain orprotecting group(s) hydrophobic protecting group(s) hydrophobic sidechain Aromatic His Aromatic hydrophobic side or hydrophobic chain orprotecting group(s) hydrophobic protecting group(s)

Where longer peptides are desired, X² and X³ can represent domains(e.g., regions of two or more amino acids of the specified type) ratherthan individual amino acids. Table 8 is intended to be illustrative andnot limiting. Using the teaching provided herein, other suitablepeptides can readily be identified.

8) Paired Amino Acids and Dipeptides.

In certain embodiments, this invention pertains to the discovery thatcertain pairs of amino acids, administered in conjunction with eachother or linked to form a dipeptide have one or more of the propertiesdescribed herein. Thus, without being bound to a particular theory, itis believed that when the pairs of amino acids are administered inconjunction with each other, as described herein, they are capableparticipating in or inducing the formation of micelles in vivo.

Similar to the other small peptides described herein, it is believedthat the pairs of peptides will associate in vivo, and demonstratephysical properties including high solubility in ethyl acetate (e.g.,greater than about 4 mg/mL), solubility in aqueous buffer at pH 7.0.Upon contacting phospholipids such as1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC), in an aqueousenvironment, it is believed the pairs of amino acids induce orparticipate in the formation of particles with a diameter ofapproximately 7.5 nm (+0.1 nm), and/or induce or participate in theformation of stacked bilayers with a bilayer dimension on the order of3.4 to 4.1 nm with spacing between the bilayers in the stack ofapproximately 2 nm, and/or also induce or participate in the formationof vesicular structures of approximately 38 nm).

Moreover, it is further believed that the pairs of amino acids candisplay one or more of the following physiologically relevantproperties:

-   -   1. They convert pro-inflammatory HDL to anti-inflammatory HDL or        make anti-inflammatory HDL more anti-inflammatory;    -   2. They decrease LDL-induced monocyte chemotactic activity        generated by artery wall cells;    -   3. They stimulate the formation and cycling of pre-β HDL;    -   4. They raise HDL cholesterol; and/or    -   5. They increase HDL paraoxonase activity.

The pairs of amino acids can be administered as separate amino acids(administered sequentially or simultaneously, e.g. in a combinedformulation) or they can be covalently coupled directly or through alinker (e.g. a PEG linker, a carbon linker, a branched linker, astraight chain linker, a heterocyclic linker, a linker formed ofderivatized lipid, etc.). In certain embodiments, the pairs of aminoacids are covalently linked through a peptide bond to form a dipeptide.In various embodiments while the dipeptides will typically comprise twoamino acids each bearing an attached protecting group, this inventionalso contemplates dipeptides wherein only one of the amino acids bearsone or more protecting groups.

The pairs of amino acids typically comprise amino acids where each aminoacid is attached to at least one protecting group (e.g., a hydrophobicprotecting group as described herein). The amino acids can be in the Dor the L form. In certain embodiments, where the amino acids comprisingthe pairs are not attached to each other, each amino acid bears twoprotecting groups (e.g., such as molecules 1 and 2 in Table 9).

TABLE 9 Illustrative amino acid pairs of this invention. Amino AcidPair/dipeptide 1. Boc-Arg-OtBu* 2. Boc-Glu-OtBu* 3. Boc-Phe-Arg-OtBu**4. Boc-Glu-Leu-OtBu** 5. Boc-Arg-Glu-OtBu*** *This would typically beadministered in conjunciton with a second amino acid. **In certainembodiments, these dipeptides would be administered in conjunction witheach other. ***In certain embodiments, this peptide would beadministered either alone or in combination with one of the otherpeptides described herein..

Suitable pairs of amino acids can readily be identified by providing thepair of protected amino acids and/or a dipeptide and then screening thepair of amino acids/dipeptide for one or more of the physical and/orphysiological properties described above. In certain embodiments, thisinvention excludes pairs of amino acids and/or dipeptides comprisingaspartic acid and phenylalanine. In certain embodiments, this inventionexcludes pairs of amino acids and/or dipeptides in which one amino acidis (−)-N—[(trans-4-isopropylcyclohexane)carbonyl]-D-phenylalanine(nateglinide).

In certain embodiments, the amino acids comprising the pair areindependently selected from the group consisting of an acidic amino acid(e.g., aspartic acid, glutamic acid, etc.), a basic amino acid (e.g.,lysine, arginine, histidine, etc.), and a non-polar amino acid (e.g.,alanine, valine, leucine, isoleucine, proline, phenylalanine,tryptophan, methionine, etc.). In certain embodiments, where the firstamino acid is acidic or basic, the second amino acid is non-polar andwhere the second amino acid is acidic or basic, the first amino acid isnon-polar. In certain embodiments, where the first amino acid is acidic,the second amino acid is basic, and vice versa. (see, e.g., Table 10).

Similar combinations can be obtained by administering pairs ofdipeptides. Thus, for example in certain embodiments, molecules 3 and 4in Table 9 would be administered in conjunction with each other.

TABLE 10 Certain generalized amino acid pairs/dipeptides. First Aminoacid Second Amino acid 1. Acidic Basic 2. Basic Acidic 3. AcidicNon-polar 4. Non-polar Acidic 5. Basic Non-polar 6. Non-polar Basic

It is noted that these amino acid pairs/dipeptides are intended to beillustrative and not limiting. Using the teaching provided herein othersuitable amino acid pairs/dipeptides can readily be determined.

D) Apo-J (G* Peptides).

In certain It was a discovery of this invention that peptides thatmimicking the amphipathic helical domains of apo J are capable ofmitigating one or more symptoms of atherosclerosis and/or otherpathologies described herein. Apolipoprotein J possesses a wide nonpolarface termed globular protein-like, or G* amphipathic helical domains.The class G amphipathic helix is found in globular proteins, and thus,the name class G. This class of amphipathic helix is characterized by arandom distribution of positively charged and negatively chargedresidues on the polar face with a narrow nonpolar face. Because of thenarrow nonpolar face this class does not readily associate withphospholipids. The G* of amphipathic helix possesses similar, but notidentical, characteristics to the G amphipathic helix. Similar to theclass G amphipathic helix, the G* class peptides possesses a randomdistribution of positively and negatively charged residues on the polarface. However, in contrast to the class G amphipathic helix which has anarrow nonpolar face, this class has a wide nonpolar face that allowsthis class to readily bind phospholipid and the class is termed G* todifferentiate it from the G class of amphipathic helix.

A number of suitable G* amphipathic peptides are described in copendingapplications U.S. Ser. No. 10/120,508, filed Apr. 5, 2002, U.S. Ser. No.10/520,207, filed Apr. 1, 2003, and PCT Application PCT/US03/09988,filed Apr. 1, 2003. In addition, a variety of suitable peptides of thisinvention that are related to G* amphipathic helical domains of apo Jare illustrated in Table 11.

TABLE 11 Preferred peptides for use in this invention related to g*amphipathic helical domains of apo J. Amino Acid Sequence SEQ ID NOLLEQLNEQFNWVSRLANLTQGE 444 LLEQLNEQFNWVSRLANL 445NELQEMSNQGSKYVNKEIQNAVNGV 446 IQNAVNGVKQIKTLIEKTNEE 447RKTLLSNLEEAKKKKEDALNETRESETKLKEL 448 PGVCNETMMALWEECK 449PCLKQTCMKFYARVCR 450 ECKPCLKQTCMKFYARVCR 451 LVGRQLEEFL 452 MNGDRIDSLLEN453 QQTHMLDVMQD 454 FSRASSIIDELFQD 455 PFLEMIHEAQQAMDI 456 PTEFIREGDDD457 RMKDQCDKCREILSV 458 PSQAKLRRELDESLQVAERLTRKYNELLKSYQ 459LLEQLNEQFNWVSRLANLTEGE 460 DQYYLRVTTVA 461 PSGVTEVVVKLFDS 462PKFMETVAEKALQEYRKKHRE 463

The peptides of this invention, however, are not limited to G* variantsof apo J. Generally speaking G* domains from essentially any otherprotein preferably apo proteins are also suitable. The particularsuitability of such proteins can readily be determined using assays forprotective activity (e.g., protecting LDL from oxidation, and the like),e.g. as illustrated herein in the Examples. Some particularly preferredproteins include G* amphipathic helical domains or variants thereof(e.g., conservative substitutions, and the like) of proteins including,but not limited to apo AI, apo AIV, apo E, apo CII, apo CIII, and thelike.

Certain preferred peptides for related to G* amphipathic helical domainsrelated to apoproteins other than apo J are illustrated in Table 12.

TABLE 12 Peptides for use in this invention related to G* amphipathichelical domains related to apoproteins other than apo J. SEQ Amino AcidSequence ID NO WDRVKDLATVYVDVLKDSGRDYVSQF 464 (Related to the 8 to 33region of apo AI) VATVMWDYFSQLSNNAKEAVEHLQK 465 (Related to the 7 to 31region of apo AIV) RWELALGRFWDYLRWVQTLSEQVQEEL 466 (Related to the 25 to51 region of apo E) LSSQVTQELRALMDETMKELKELKAYKSELEEQLT 467 (Related tothe 52 to 83 region of apo E) ARLSKELQAAQARLGADMEDVCGRLV 468 (Related tothe 91 to 116 region of apo E) VRLASHLRKLRKRLLRDADDLQKRLA 469 (Relatedto the 135 to 160 region of apo E) PLVEDMQRQWAGLVEKVQA 470 (267 to 285of apo E.27) MSTYTGIFTDQVLSVLK 471 (Related to the 60 to 76 region ofapo CII) LLSFMQGYMKHATKTAKDALSS 472 (Related to the 8 to 29 region ofapo CIII)

Additional illustrative G* peptides are shown in Table 13.

TABLE 13 Additional illustrative G* peptides. SEQ ID Peptide NOAc-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 473Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Phe-Tyr-His-Leu-Thr-Glu-Gly-Ser- 474Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Leu-Tyr-His-Leu-Thr-Glu-Gly-Ser- 475Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Val-Tyr-His-Leu-Thr-Glu-Gly-Ser- 476Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Tyr-Ile-Trp-His-Leu-Thr-Glu-Gly-Ser- 477Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Phe-Thr-Glu-Gly-Ser- 478Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Phe-Tyr-His-Ile-Thr-Glu-Gly-Ser- 479Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Leu-Tyr-His-Val-Thr-Glu-Gly-Ser- 480Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Val-Tyr-His-Tyr-Thr-Glu-Gly-Ser- 481Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Tyr-Ile-Trp-His-Phe-Thr-Glu-Gly-Ser- 482Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Tyr-Ile-Trp-His-Ile-Thr-Glu-Gly-Ser- 483Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Tyr-Ile-Trp-His-Val-Thr-Glu-Gly-Ser- 484Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Tyr-Ile-Trp-His-Tyr-Thr-Glu-Gly-Ser- 485Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Phe-Ile-Trp-His-Leu-Thr-Glu-Gly-Ser- 486Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Leu-Ile-Trp-His-Leu-Thr-Glu-Gly-Ser- 487Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Ile-Ile-Trp-His-Leu-Thr-Glu-Gly-Ser- 488Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Tyr-Ile-Trp-Phe-Leu-Thr-Glu-Gly-Ser- 489Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-Phe-Leu-Thr-Glu-Gly-Ser- 490Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-Leu-Leu-Thr-Glu-Gly-Ser- 491Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Phe-Thr-Glu-Gly-Ser- 492Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Tyr-Thr-Glu-Gly-Ser- 493Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Ile-Thr-Glu-Gly-Ser- 494Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Ser-Glu-Gly-Ser- 495Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Asp-Gly-Ser- 496Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Thr- 497Ser-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 498Thr-Glu-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 499Thr-Asp-Phe-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 500Thr-Asp-Tyr-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 501Thr-Asp-Ile-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 502Thr-Asp-Val-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 503Thr-Asp-Leu-Lys-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 504Thr-Asp-Leu-Arg-Ser-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 505Thr-Asp-Leu-Arg-Thr-Asp-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 506Thr-Asp-Ile-Lys-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 507Thr-Asp-Ile-Arg-Ser-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 508Thr-Asp-Ile-Lys-Ser-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 509Thr-Asp-Ile-Lys-Ser-Asp-Gly-NH₂Ac-Arg-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 510Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Tyr-Ile-Trp-His-Leu-Thr-Glu-Gly-Ser- 511Thr-Asp-Ile-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 512Thr-Asp-Ile-Arg-Thr-Asp-Gly-NH₂Ac-Arg-Trp-Ile-Phe-His-Leu-Thr-Glu-Gly-Ser- 513Thr-Asp-Ile-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 514Thr-Asp-Leu-Lys-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Ile-Tyr-His-Leu-Thr-Asp-Gly-Ser- 515Thr-Asp-Ile-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Ile-Tyr-His-Leu-Thr-Asp-Gly-Ser- 516Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Ile-Tyr-Phe-Leu-Thr-Glu-Gly-Ser- 517Thr-Asp-Ile-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Ile-Tyr-Phe-Leu-Thr-Glu-Gly-Ser- 518Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Phe-Tyr-His-Leu-Thr-Glu-Gly-Ser- 519Thr-Asp-Phe-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Phe-Tyr-His-Leu-Thr-Glu-Gly-Ser- 520Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Phe-His-Leu-Thr-Glu-Gly-Ser- 521Thr-Asp-Ile-Arg-Thr-Asp-Gly-NH₂Ac-Arg-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 522Thr-Asp-Ile-Arg-Thr-Asp-Gly-NH₂Ac-Arg-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 523Thr-Asp-Leu-Arg-Thr-Asp-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 524Thr-Asp-Ile-Lys-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 525Thr-Asp-Ile-Lys-Thr-Asp-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 526Thr-Asp-Phe-Lys-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 527Thr-Asp-Tyr-Lys-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Ile-Tyr-His-Leu-Thr-Glu-Gly-Ser- 528Thr-Asp-Ile-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Phe-Tyr-His-Phe-Thr-Glu-Gly-Ser- 529Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Phe-Tyr-His-Phe-Thr-Glu-Gly-Ser- 530Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Phe-Tyr-His-Phe-Thr-Glu-Gly-Ser- 531Thr-Asp-Phe-Arg-Thr-Glu-Gly-NH₂Ac-Lys-Trp-Phe-Tyr-His-Phe-Thr-Asp-Gly-Ser- 532Thr-Asp-Ile-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Phe-Tyr-His-Phe-Thr-Glu-Gly-Ser- 533Thr-Asp-Leu-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Phe-Tyr-His-Phe-Thr-Glu-Gly-Ser- 534Thr-Asp-Phe-Arg-Thr-Glu-Gly-NH₂Ac-Arg-Trp-Phe-Tyr-His-Phe-Thr-Glu-Gly-Ser- 535Thr-Asp-Phe-Arg-Thr-Asp-Gly-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Leu- 536Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Leu- 537Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Asp-Glu-Phe-Lys-Ser-Leu- 538Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Asp-Phe-Lys-Ser-Leu- 539Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Val-Glu-Glu-Phe-Lys-Ser-Leu- 540Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Lys-Cys-Val-Asp-Asp-Phe-Lys-Ser-Leu- 541Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Arg-Cys-Val-Glu-Glu-Phe-Lys-Ser-Leu- 542Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Val-Asp-Asp-Phe-Lys-Ser-Leu- 543Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 544Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Ile- 545Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Val- 546Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Val-Glu-Glu-Phe-Lys-Ser-Tyr- 547Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 548Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Val-Glu-Glu-Phe-Lys-Ser-Ile- 549Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Val-Glu-Glu-Phe-Lys-Ser-Val- 550Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Val-Glu-Glu-Phe-Lys-Ser-Tyr- 551Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 552Thr-Thr-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Ile- 553Ser-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Val- 554Ser-Thr-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Tyr- 555Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 556Thr-Thr-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 557Ser-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 558Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 559Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 560Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 561Thr-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 562Thr-Ser-Cys-Phe-Glu-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 563Thr-Ser-Cys-Leu-Glu-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 564Thr-Ser-Cys-Ile-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Leu-Lys-Ser-Phe- 565Thr-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 566Thr-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 567Thr-Ser-Cys-Phe-Glu-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 568Thr-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 569Thr-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 570Thr-Ser-Cys-Phe-Glu-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 571Ser-Ser-Cys-Phe-Glu-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 572Gln-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 573Gln-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Gln-Phe- 574Thr-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Gln-Leu- 575Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 576Gln-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Gln-Phe- 577Thr-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Phe- 578Thr-Ser-Cys-Phe-Glu-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 579Thr-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 580Thr-Ser-Cys-Phe-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Arg-Cys-Val-Glu-Glu-Phe-Lys-Ser-Leu- 581Thr-Ser-Cys-Leu-Glu-Ser-Lys-Ala-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Leu- 582Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Glu-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 583Thr-Ser-Cys-Phe-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Asp-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 584Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Asp-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 585Thr-Ser-Cys-Leu-Glu-Ser-Lys-Phe-Phe-NH₂Ac-Asp-Lys-Cys-Phe-Glu-Glu-Leu-Lys-Ser-Phe- 586Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Glu-Arg-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 587Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Glu-Lys-Ala-Val-Glu-Glu-Phe-Lys-Ser-Phe- 588Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Lys-Ala-Val-Glu-Glu-Phe-Lys-Ser-Phe- 589Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Glu-Lys-Ala-Val-Glu-Glu-Phe-Lys-Ser-Phe- 590Thr-Ser-Ala-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Lys-Ala-Val-Glu-Glu-Phe-Lys-Ser-Phe- 591Thr-Ser-Ala-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Arg-Ala-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 592Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Asp-Arg-Ala-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 593Thr-Ser-Ala-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Asp-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Phe- 594Thr-Ser-Cys-Phe-Glu-Ser-Lys-Phe-Phe-NH₂Ac-Glu-Lys-Cys-Tyr-Glu-Glu-Phe-Lys-Ser-Phe- 595Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Asp-Lys-Cys-Trp-Glu-Glu-Phe-Lys-Ser-Phe- 596Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Glu-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Tyr- 597Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Glu-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Trp- 598Thr-Ser-Cys-Leu-Asp-Ser-Lys-Phe-Phe-NH₂Ac-Glu-Lys-Cys-Val-Glu-Glu-Phe-Lys-Ser-Trp- 599Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂Ac-Asp-Lys-Cys-Phe-Glu-Glu-Phe-Lys-Ser-Trp- 600Thr-Ser-Cys-Leu-Asp-Ser-Lys-Ala-Phe-NH₂

Other suitable peptides include, but are not limited to the peptides ofTable 14.

TABLE 14 Illustrative peptides having an improved hydrophobic phase. SEQID Name Sequence NO V2W3A5F1017- Ac-Asp-Val-Trp-Lys-Ala-Ala-Tyr- 601D-4F Asp-Lys-Phe-Ala-Glu-Lys-Phe- Lys-Glu-Phe-Phe-NH₂ V2W3F10-D-4FAc-Asp-Val-Trp-Lys-Ala-Phe-Tyr- 602 Asp-Lys-Phe-Ala-Glu-Lys-Phe-Lys-Glu-Ala-Phe-NH₂ W3-D-4F Ac-Asp-Phe-Trp-Lys-Ala-Phe-Tyr- 603Asp-Lys-Val-Ala-Glu-Lys-Phe- Lys-Glu-Ala-Phe-NH₂

The peptides described here (V2W3A5F10,17-D-4F; V2W3F10-D-4F; W3-D-4F)may be more potent than the original D-4F.

Still other suitable peptides include, but are not limited to:P¹-Dimethyltyrosine-D-Arg-Phe-Lys-P² (SEQ ID NO:604) andP¹-Dimethyltyrosine-Arg-Glu-Leu-P² where P1 and P2 are protecting groupsas described herein. In certain embodiments, these peptides include, butare not limited to BocDimethyltyrosine-D-Arg-Phe-Lys(OtBu) andBocDimethyltyrosine-Arg-Glu-Leu(OtBu).

In certain embodiments, the peptides of this invention include peptidescomprising or consisting of the amino acid sequence LAEYHAK (SEQ IDNO:605) comprising at least one D amino acid and/or at least one or twoterminal protecting groups. In certain embodiments, this inventionincludes a A peptide that ameliorates one or more symptoms of aninflammatory condition, wherein the peptide: ranges in length from about3 to about 10 amino acids; comprises an amino acid sequence where thesequence comprises acidic or basic amino acids alternating with aromaticor hydrophobic amino acids; comprises hydrophobic terminal amino acidsor terminal amino acids bearing a hydrophobic protecting group; is notthe sequence LAEYHAK (SEQ ID NO:606) comprising all L amino acids; wherethe peptide converts pro-inflammatory HDL to anti-inflammatory HDLand/or makes anti-inflammatory HDL more anti-inflammatory.

It is also noted that the peptides listed in the Tables herein are notfully inclusive. Using the teaching provided herein, other suitablepeptides can routinely be produced (e.g. by conservative orsemi-conservative substitutions (e.g. D replaced by E), extensions,deletions, and the like). Thus, for example, one embodiment utilizestruncations of any one or more of peptides identified by SEQ IDNos:444-472.

Longer peptides are also suitable. Such longer peptides may entirelyform a class G or G* amphipathic helix, or the G amphipathic helix(helices) can form one or more domains of the peptide. In addition, thisinvention contemplates multimeric versions of the peptides. Thus, forexample, the peptides illustrated in the tables herein can be coupledtogether (directly or through a linker (e.g. a carbon linker, or one ormore amino acids) with one or more intervening amino acids). Suitablelinkers include, but are not limited to Proline (-Pro-), Gly₄Ser₃ (SEQID NO: 607), (Gly₄Ser)₃ (SEQ ID NO: 608) and the like. Thus, oneillustrative multimeric peptide according to this invention is(D-J336)-P-(D-J336) (i.e.Ac-L-L-E-Q-L-N-E-Q-F—N—W-V-S-R-L-A-N-L-T-Q-G-E-P-L-L-E-Q-L-N-E-Q-F-N-W-V-S-R-L-A-N-L-T-Q-G-E-NH₂,SEQ ID NO: 609).

This invention also contemplates the use of “hybrid” peptides comprisinga one or more G or G* amphipathic helical domains and one or more classA amphipathic helices. Suitable class A amphipathic helical peptides aredescribed in PCT publication WO 02/15923. Thus, by way of illustration,one such “hybrid” peptide is (D-J336)-Pro-(4F) (i.e.Ac-L-L-E-Q-L-N-E-Q-F-N-W-V-S-R-L-A-N-L-T-Q-G-E-P-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F—NH₂,SEQ ID NO: 610), and the like.

Using the teaching provided herein, one of skill can routinely modifythe illustrated amphipathic helical peptides to produce other suitableapo J variants and/or amphipathic G and/or A helical peptides of thisinvention. For example, routine conservative or semi-conservativesubstitutions (e.g., E for D) can be made of the existing amino acids.The effect of various substitutions on lipid affinity of the resultingpeptide can be predicted using the computational method described byPalgunachari et al. (1996) Arteriosclerosis, Thrombosis, & VascularBiology 16: 328-338. The peptides can be lengthened or shortened as longas the class helix structure(s) are preserved. In addition,substitutions can be made to render the resulting peptide more similarto peptide(s) endogenously produced by the subject species.

While, in preferred embodiments, the peptides of this invention utilizenaturally-occurring amino acids or D forms of naturally occurring aminoacids, substitutions with non-naturally occurring amino acids (e.g.,methionine sulfoxide, methionine methylsulfonium, norleucine,episilon-aminocaproic acid, 4-aminobutanoic acid,tetrahydroisoquinoline-3-carboxylic acid, 8-aminocaprylic acid,4-aminobutyric acid, Lys(N(epsilon)-trifluoroacetyl), α-aminoisobutyricacid, and the like) are also contemplated.

New peptides can be designed and/or evaluated using computationalmethods. Computer programs to identify and classify amphipathic helicaldomains are well known to those of skill in the art and many have beendescribed by Jones et al. (1992) J. Lipid Res. 33: 287-296). Suchprograms include, but are not limited to the helical wheel program(WHEEL or WHEEL/SNORKEL), helical net program (HELNET, HELNET/SNORKEL,HELNET/Angle), program for addition of helical wheels (COMBO orCOMBO/SNORKEL), program for addition of helical nets (COMNET,COMNET/SNORKEL, COMBO/SELECT, COMBO/NET), consensus wheel program(CONSENSUS, CONSENSUS/SNORKEL), and the like.

E) Blocking Groups and D Residues.

While the various peptides and/or amino acid pairs described herein maybe be shown with no protecting groups, in certain embodiments (e.g.particularly for oral administration), they can bear one, two, three,four, or more protecting groups. The protecting groups can be coupled tothe C- and/or N-terminus of the peptide(s) and/or to one or moreinternal residues comprising the peptide(s) (e.g., one or more R-groupson the constituent amino acids can be blocked). Thus, for example, incertain embodiments, any of the peptides described herein can bear, e.g.an acetyl group protecting the amino terminus and/or an amide groupprotecting the carboxyl terminus. One example of such a “dual protectedpeptide is Ac-L-L-E-Q-L-N-E-Q-F-N-W-V-S—R-L-A-N-L-T-Q-G-E-NH₂ (SEQ IDNO:444 with blocking groups), either or both of these protecting groupscan be eliminated and/or substituted with another protecting group asdescribed herein.

Without being bound by a particular theory, it was a discovery of thisinvention that blockage, particularly of the amino and/or carboxyltermini of the subject peptides of this invention greatly improves oraldelivery and significantly increases serum half-life.

A wide number of protecting groups are suitable for this purpose. Suchgroups include, but are not limited to acetyl, amide, and alkyl groupswith acetyl and alkyl groups being particularly preferred for N-terminalprotection and amide groups being preferred for carboxyl terminalprotection. In certain particularly preferred embodiments, theprotecting groups include, but are not limited to alkyl chains as infatty acids, propeonyl, formyl, and others. Particularly preferredcarboxyl protecting groups include amides, esters, and ether-formingprotecting groups. In one preferred embodiment, an acetyl group is usedto protect the amino terminus and an amide group is used to protect thecarboxyl terminus. These blocking groups enhance the helix-formingtendencies of the peptides. Certain particularly preferred blockinggroups include alkyl groups of various lengths, e.g. groups having theformula: CH₃—(CH₂)_(n)—CO— where n ranges from about 1 to about 20,preferably from about 1 to about 16 or 18, more preferably from about 3to about 13, and most preferably from about 3 to about 10.

In certain particularly preferred embodiments, the protecting groupsinclude, but are not limited to alkyl chains as in fatty acids,propeonyl, formyl, and others. Particularly preferred carboxylprotecting groups include amides, esters, and ether-forming protectinggroups. In one preferred embodiment, an acetyl group is used to protectthe amino terminus and an amide group is used to protect the carboxylterminus. These blocking groups enhance the helix-forming tendencies ofthe peptides. Certain particularly preferred blocking groups includealkyl groups of various lengths, e.g. groups having the formula:CH₃—(CH₂)_(n)—CO— where n ranges from about 3 to about 20, preferablyfrom about 3 to about 16, more preferably from about 3 to about 13, andmost preferably from about 3 to about 10.

Other protecting groups include, but are not limited to Fmoc,t-butoxycarbonyl (t-BOC), 9-fluoreneacetyl group, 1-fluorenecarboxylicgroup, 9-florenecarboxylic group, 9-fluorenone-1-carboxylic group,benzyloxycarbonyl, Xanthyl (Xan), Trityl (Trt), 4-methyltrityl (Mtt),4-methoxytrityl (Mmt), 4-methoxy-2,3,6-trimethyl-benzenesulphonyl (Mtr),Mesitylene-2-sulphonyl (Mts), 4,4-dimethoxybenzhydryl (Mbh), Tosyl(Tos), 2,2,5,7,8-pentamethyl chroman-6-sulphonyl (Pmc), 4-methylbenzyl(MeBzl), 4-methoxybenzyl (MeOBzl), Benzyloxy (BzlO), Benzyl (Bzl),Benzoyl (Bz), 3-nitro-2-pyridinesulphenyl (Npys),1-(4,4-dimentyl-2,6-diaxocyclohexylidene)ethyl (Dde), 2,6-dichlorobenzyl(2,6-DiCl-Bzl), 2-chlorobenzyloxycarbonyl (2-Cl-Z),2-bromobenzyloxycarbonyl (2-Br-Z), Benzyloxymethyl (Bom), cyclohexyloxy(cHxO),t-butoxymethyl (Bum), t-butoxy (tBuO), t-Butyl (tBu), Acetyl(Ac), and Trifluoroacetyl (TFA).

Protecting/blocking groups are well known to those of skill as aremethods of coupling such groups to the appropriate residue(s) comprisingthe peptides of this invention (see, e.g., Greene et al., (1991)Protective Groups in Organic Synthesis, 2nd ed., John Wiley & Sons, Inc.Somerset, N.J.). In one preferred embodiment, for example, acetylationis accomplished during the synthesis when the peptide is on the resinusing acetic anhydride. Amide protection can be achieved by theselection of a proper resin for the synthesis. During the synthesis ofthe peptides described herein in the examples, rink amide resin wasused. After the completion of the synthesis, the semipermanentprotecting groups on acidic bifunctional amino acids such as Asp and Gluand basic amino acid Lys, hydroxyl of Tyr are all simultaneouslyremoved. The peptides released from such a resin using acidic treatmentcomes out with the n-terminal protected as acetyl and the carboxylprotected as NH₂ and with the simultaneous removal of all of the otherprotecting groups.

In certain particularly preferred embodiments, the peptides comprise oneor more D-form (dextro rather than levo) amino acids as describedherein. In certain embodiments at least two enantiomeric amino acids,more preferably at least 4 enantiomeric amino acids and most preferablyat least 8 or 10 enantiomeric amino acids are “D” form amino acids. Incertain embodiments every other, or even every amino acid (e.g. everyenantiomeric amino acid) of the peptides described herein is a D-formamino acid.

In certain embodiments at least 50% of the enantiomeric amino acids are“D” form, more preferably at least 80% of the enantiomeric amino acidsare “D” form, and most preferably at least 90% or even all of theenantiomeric amino acids are “D” form amino acids.

F) Peptide Mimetics.

In addition to the peptides described herein, peptidomimetics are alsocontemplated. Peptide analogs are commonly used in the pharmaceuticalindustry as non-peptide drugs with properties analogous to those of thetemplate peptide. These types of non-peptide compound are termed“peptide mimetics” or “peptidomimetics” (Fauchere (1986) Adv. Drug Res.15: 29; Veber and Freidinger (1985) TINS p. 392; and Evans et al. (1987)J. Med. Chem. 30: 1229) and are usually developed with the aid ofcomputerized molecular modeling. Peptide mimetics that are structurallysimilar to therapeutically useful peptides may be used to produce anequivalent therapeutic or prophylactic effect.

Generally, peptidomimetics are structurally similar to a paradigmpolypeptide (e.g. SEQ ID NO:5 shown in Table 1), but have one or morepeptide linkages optionally replaced by a linkage selected from thegroup consisting of: —CH₂NH—, —CH₂S—, —CH₂—CH₂—, —CH═CH— (cis andtrans), —COCH₂—, —CH(OH)CH₂—, —CH₂SO—, etc. by methods known in the artand further described in the following references: Spatola (1983) p. 267in Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, B.Weinstein, eds., Marcel Dekker, New York; Spatola (1983) Vega Data 1(3)Peptide Backbone Modifications. (general review); Morley (1980) TrendsPharm Sci pp. 463-468 (general review); Hudson et al. (1979) Int J PeptProt Res 14:177-185 (—CH₂NH—, CH₂CH₂—); Spatola et al. (1986) Life Sci38:1243-1249 (—CH₂—S); Hann, (1982) J Chem Soc Perkin Trans 1307-314(—CH—CH—, cis and trans); Almquist et al. (1980) J Med. Chem.23:1392-1398 (—COCH₂—); Jennings-White et al. (1982) Tetrahedron Lett.23:2533 (—COCH₂—); Szelke et al., European Appln. EP 45665 (1982) CA:97:39405 (1982) (—CH(OH)CH₂—); Holladay et al. (1983) Tetrahedron Lett24:4401-4404 (—C(OH)CH₂—); and Hruby (1982) Life Sci., 31:189-199(—CH₂—S—)).

One particularly preferred non-peptide linkage is —CH₂NH—. Such peptidemimetics may have significant advantages over polypeptide embodiments,including, for example: more economical production, greater chemicalstability, enhanced pharmacological properties (half-life, absorption,potency, efficacy, etc.), reduced antigenicity, and others.

In addition, circularly permutations of the peptides described herein orconstrained peptides (including cyclized peptides) comprising aconsensus sequence or a substantially identical consensus sequencevariation may be generated by methods known in the art (Rizo andGierasch (1992) Ann. Rev. Biochem. 61: 387); for example, by addinginternal cysteine residues capable of forming intramolecular disulfidebridges which cyclize the peptide.

G) Small Organic Molecules.

In certain embodiments, the active agents of this invention includesmall organic molecules, e.g. as described in copending application U.S.Ser. No. 60/600,925, filed Aug. 11, 2004. In various embodiments thesmall organic molecules are similar to, and in certain cases, mimeticsof the tetra- and penta-peptides described in copending application U.S.Ser. No. 10/649,378, filed on Aug. 26, 2003 and U.S. Ser. No.60/494,449, filed on August 11.

The small organic molecules of this invention typically have molecularweights less than about 900 Daltons. Typically the molecules are arehighly soluble in ethyl acetate (e.g., at concentrations equal to orgreater than 4 mg/mL), and also are soluble in aqueous buffer at pH 7.0.

Contacting phospholipids such as1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), with the smallorganic molecules of this invention in an aqueous environment typicallyresults in the formation of particles with a diameter of approximately7.5 nm (±0.1 nm). In addition, stacked bilayers are often formed with abilayer dimension on the order of 3.4 to 4.1 nm with spacing between thebilayers in the stack of approximately 2 nm. Vesicular structures ofapproximately 38 nm are also often formed. Moreover, when the moleculesof this invention are administered to a mammal they render HDL moreanti-inflammatory and mitigate one or more symptoms of atherosclerosisand/or other conditions characterized by an inflammatory response.

Thus, in certain embodiments, the small organic molecule is one thatameliorates one or more symptoms of a pathology characterized by aninflammatory response in a mammal (e.g. atherosclerosis), where thesmall molecule is soluble in in ethyl acetate at a concentration greaterthan 4 mg/mL, is soluble in aqueous buffer at pH 7.0, and, whencontacted with a phospholipid in an aqueous environment, forms particleswith a diameter of approximately 7.5 nm and forms stacked bilayers witha bilayer dimension on the order of 3.4 to 4.1 nm with spacing betweenthe bilayers in the stack of approximately 2 nm, and has a molecularweight les than 900 daltons.

In certain embodiment, the molecule has the formula:

where P¹, P², P³, and P⁴ are independently selected hydrophobicprotecting groups; R¹ and R⁴ are independently selected amino acid Rgroups; n, i, x, y, and z are independently zero or 1 such that when nand x are both zero, R is a hydrophobic group and when y and i are bothzero, R⁴ is a hydrophobic group; R² and R³ are acidic or basic groups atpH 7.0 such that when R² is acidic, R³ is basic and when R² is basic, R³is acidic; and R⁵, when present is selected from the group consisting ofan aromatic group, an aliphatic group, a positively charged group, or anegatively charged group. In certain embodiments, R² or R³ is—(CH₂)j-COOH where j=1, 2, 3, or 4 and/or —(CH₂)j-NH₂ where j=1, 2, 3,4, or 5, or —(CH₂)j-NH-C(═NH)—NH₂ where n=1, 2, 3 or 4. In certainembodiments, R², R³, and R⁵, when present, are amino acid R groups.Thus, for example, In various embodiments R² and R³ are independently anaspartic acid R group, a glutamic acid R group, a lysine R group, ahistidine R group, or an arginine R group (e.g., as illustrated in Table1).

In certain embodiments, R is selected from the group consisting of a LysR group, a Trp R group, a Phe R group, a Leu R group, an Orn R group, pra norLeu R group.

In certain embodiments, R⁴ is selected from the group consisting of aSer R group, a Thr R group, an Ile R group, a Leu R group, a norLeu Rgroup, a Phe R group, or a Tyr R group.

In various embodiments x is 1, and R⁵ is an aromatic group (e.g., a TrpR group).

In various embodiments at least one of n, x, y, and i is 1 and P¹, P²,P³, and P⁴ when present, are independently selected from the groupconsisting of polyethylene glycol (PEG), an acetyl, amide, a 3 to 20carbon alkyl group, fmoc, 9-fluoreneacetyl group, 1-fluorenecarboxylicgroup, 9-fluorenecarboxylic, 9-fluorenone-1-carboxylic group,benzyloxycarbonyl, xanthyl (Xan), Trityl (Trt), 4-methyltrityl (Mtt),4-methoxytrityl (Mmt), 4-methoxy-2,3,6-trimethyl-benzenesulphonyl (Mtr),Mesitylene-2-sulphonyl (Mts), 4,4-dimethoxybenzhydryl (Mbh), Tosyl(Tos), 2,2,5,7,8-pentamethyl chroman-6-sulphonyl (Pmc), 4-methylbenzyl(MeBzl), 4-methoxybenzyl (MeOBzl), benzyloxy (BzlO), benzyl (Bzl),benzoyl (Bz), 3-nitro-2-pyridinesulphenyl (Npys),1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde), 2,6-dichlorobenzyl(2,6-DiCl-Bzl), 2-chlorobenzyloxycarbonyl (2-Cl-Z),2-bromobenzyloxycarbonyl (2-Br-Z), benzyloxymethyl (Bom),t-butoxycarbonyl (Boc), cyclohexyloxy (cHxO), t-butoxymethyl (Bum),t-butoxy (tBuO), t-Butyl (tBu), a propyl group, a butyl group, a pentylgroup, a hexyl group, and trifluoroacetyl (TFA). In certain embodiments,P¹ when present and/or P² when present are independently selected fromthe group consisting of Boc-, Fmoc-, and Nicotinyl- and/or P³ whenpresent and/or P⁴ when present are independently selected from the groupconsisting of tBu, and OtBu.

While a number of protecting groups (P¹, P², P³, P⁴) are illustratedabove, this list is intended to be illustrative and not limiting. Inview of the teachings provided herein, a number of otherprotecting/blocking groups will also be known to one of skill in theart. Such blocking groups can be selected to minimize digestion (e.g.,for oral pharmaceutical delivery), and/or to increaseuptake/bioavailability (e.g., through mucosal surfaces in nasaldelivery, inhalation therapy, rectal administration), and/or to increaseserum/plasma half-life. In certain embodiments, the protecting groupscan be provided as an excipient or as a component of an excipient.

In certain embodiments, z is zero and the molecule has the formula:

where P¹, P², P³, P⁴, R¹, R², R³, R⁴, n, x, y, and i are as describedabove.

In certain embodiments, z is zero and the molecule has the formula:

where R¹, R², R³, and R⁴ are as described above.

In one embodiment, the molecule has the formula:

In certain embodiments, this invention contemplates small moleculeshaving one or more of the physical and/or functional propertiesdescribed herein and having the formula:

where P¹, P², P³, and P⁴ are independently selected hydrophobicprotecting groups as described above, n, x, and y are independently zeroor 1; j, k, and 1 are independently zero, 1, 2, 3, 4, or 5; and R² andR³ are acidic or basic groups at pH 7.0 such that when R² is acidic, R³is basic and when R² is basic, R³ is acidic. In certain preferredembodiments, the small molecule is soluble in water; and the smallmolecule has a molecular weight less than about 900 Daltons. In certainembodiments, n, x, y, j, and 1 are 1; and k is 4.

In certain embodiments, P¹ and/or P² are aromatic protecting groups. Incertain embodiments, R² and R³ are amino acid R groups, e.g., asdescribed above. In various embodiments least one of n, x, and y, is 1and P¹, P², P³ and P⁴ when present, are independently protecting groups,e.g. as described above selected from the group consisting ofpolyethylene glycol (PEG), an acetyl, amide, 3 to 20 carbon alkylgroups, Fmoc, 9-fluoreneacetyl group, 1-fluorenecarboxylic group,9-fluorenecarboxylic, 9-fluorenone-1-carboxylic group,benzyloxycarbonyl, Xanthyl (Xan), Trityl (Trt), 4-methyltrityl (Mtt),4-methoxytrityl (Mmt), 4-methoxy-2,3,6-trimethyl-benzenesulphonyl (Mtr),Mesitylene-2-sulphonyl (Mts), -4,4-dimethoxybenzhydryl (Mbh) Tosyl(Tos), 2,2,5,7,8-penta

II. Functional Assays of Active Agents.

Certain active agents for use in the methods of this invention aredescribed herein by various formulas (e.g., Formula I, above) and/or byparticular sequences. In certain embodiments, preferred active agents ofthis invention are characterized by one or more of the followingfunctional properties:

-   -   1. They convert pro-inflammatory HDL to anti-inflammatory HDL or        make anti-inflammatory HDL more anti-inflammatory;    -   2. They decrease LDL-induced monocyte chemotactic activity        generated by artery wall cells;    -   3. They stimulate the formation and cycling of pre-β HDL;    -   4. They raise HDL cholesterol; and/or    -   5. They increase HDL paraoxonase activity.

The specific agents disclosed herein, and/or agents corresponding to thevarious formulas described herein can readily be tested for one or moreof these activities as desired.

Methods of screening for each of these functional properties are wellknown to those of skill in the art. In particular, it is noted thatassays for monocyte chemotactic activity, HDL cholesterol, and HDL HDLparaoxonase activity are illustrated in PCT/US01/26497 (WO 2002/15923).

III. Peptide Preparation.

The peptides used in this invention can be chemically synthesized usingstandard chemical peptide synthesis techniques or, particularly wherethe peptide does not comprise “D” amino acid residues, can berecombinantly expressed. In certain embodiments, even peptidescomprising “D” amino acid residues are recombinantly expressed. Wherethe polypeptides are recombinantly expressed, a host organism (e.g.bacteria, plant, fungal cells, etc.) in cultured in an environment whereone or more of the amino acids is provided to the organism exclusivelyin a D form. Recombinantly expressed peptides in such a system thenincorporate those D amino acids.

In preferred embodiments the peptides are chemically synthesized by anyof a number of fluid or solid phase peptide synthesis techniques knownto those of skill in the art. Solid phase synthesis in which theC-terminal amino acid of the sequence is attached to an insolublesupport followed by sequential addition of the remaining amino acids inthe sequence is a preferred method for the chemical synthesis of thepolypeptides of this invention. Techniques for solid phase synthesis arewell known to those of skill in the art and are described, for example,by Barany and Merrifield (1963) Solid-Phase Peptide Synthesis; pp. 3-284in The Peptides: Analysis, Synthesis, Biology. Vol. 2: Special Methodsin Peptide Synthesis, Part A.; Merrifield et al. (1963) J. Am. Chem.Soc., 85: 2149-2156, and Stewart et al. (1984) Solid Phase PeptideSynthesis, 2nd ed. Pierce Chem. Co., Rockford, Ill.

In certain embodiments, the peptides are synthesized by the solid phasepeptide synthesis procedure using a benzhyderylamine resin (BeckmanBioproducts, 0.59 mmol of NH₂/g of resin) as the solid support. The COOHterminal amino acid (e.g., t-butylcarbonyl-Phe) is attached to the solidsupport through a 4-(oxymethyl)phenacetyl group. This is a more stablelinkage than the conventional benzyl ester linkage, yet the finishedpeptide can still be cleaved by hydrogenation. Transfer hydrogenationusing formic acid as the hydrogen donor is used for this purpose.Detailed protocols used for peptide synthesis and analysis ofsynthesized peptides are described in a miniprint supplementaccompanying Anantharamaiah et al. (1985) J. Biol. Chem., 260(16):10248-10255.

It is noted that in the chemical synthesis of peptides, particularlypeptides comprising D amino acids, the synthesis usually produces anumber of truncated peptides in addition to the desired full-lengthproduct. The purification process (e.g. HPLC) typically results in theloss of a significant amount of the full-length product.

It was a discovery of this invention that, in the synthesis of a Dpeptide (e.g. D-4), in order to prevent loss in purifying the longestform one can dialyze and use the mixture and thereby eliminate the lastHPLC purification. Such a mixture loses about 50% of the potency of thehighly purified product (e.g. per wt of protein product), but themixture contains about 6 times more peptide and thus greater totalactivity.

IV. Pharmaceutical Formulations.

In order to carry out the methods of the invention, one or more agents(e.g. peptides, peptide mimetics, lipids) of this invention areadministered, e.g. to an individual diagnosed as having impairedarteriole function or as being at risk of impaired arteriole function(e.g. in the brain or kidney). The agents (e.g. peptides, peptidemimetics, lipids) can be administered in the “native” form or, ifdesired, in the form of salts, esters, amides, prodrugs, derivatives,and the like, provided the salt, ester, amide, prodrug or derivative issuitable pharmacologically, i.e., effective in the present method.Salts, esters, amides, prodrugs and other derivatives of the activeagents may be prepared using standard procedures known to those skilledin the art of synthetic organic chemistry and described, for example, byMarch (1992) Advanced Organic Chemistry; Reactions, Mechanisms andStructure, 4th Ed. N.Y. Wiley-Interscience.

For example, acid addition salts are prepared from the free base usingconventional methodology, that typically involves reaction with asuitable acid. Generally, the base form of the drug is dissolved in apolar organic solvent such as methanol or ethanol and the acid is addedthereto. The resulting salt either precipitates or may be brought out ofsolution by addition of a less polar solvent. Suitable acids forpreparing acid addition salts include both organic acids, e.g., aceticacid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malicacid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaricacid, citric acid, benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid,salicylic acid, and the like, as well as inorganic acids, e.g.,hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like. An acid addition salt may be reconvertedto the free base by treatment with a suitable base. Particularlypreferred acid addition salts of the active agents herein are halidesalts, such as may be prepared using hydrochloric or hydrobromic acids.Conversely, preparation of basic salts of the agents (e.g. peptides,peptide mimetics) are prepared in a similar manner using apharmaceutically acceptable base such as sodium hydroxide, potassiumhydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine, or thelike. Particularly preferred basic salts include alkali metal salts,e.g., the sodium salt, and copper salts.

Preparation of Esters Typically Involves Functionalization of Hydroxyland/or carboxyl groups which may be present within the molecularstructure of the drug. The esters are typically acyl-substitutedderivatives of free alcohol groups, i.e., moieties that are derived fromcarboxylic acids of the formula RCOOH where R is alkyl, and preferablyis lower alkyl. Esters can be reconverted to the free acids, if desired,by using conventional hydrogenolysis or hydrolysis procedures.

Amides and prodrugs may also be prepared using techniques known to thoseskilled in the art or described in the pertinent literature. Forexample, amides may be prepared from esters, using suitable aminereactants, or they may be prepared from an anhydride or an acid chlorideby reaction with ammonia or a lower alkyl amine. Prodrugs are typicallyprepared by covalent attachment of a moiety that results in a compoundthat is therapeutically inactive until modified by an individual'smetabolic system.

The agents (e.g. peptides, peptide mimetics, lipids) identified hereinare useful for parenteral, topical, oral, nasal (or otherwise inhaled),rectal, or local administration, such as by aerosol or transdermally,for prophylactic and/or therapeutic treatment of atherosclerosis and/orsymptoms thereof. The pharmaceutical compositions can be administered ina variety of unit dosage forms depending upon the method ofadministration. Suitable unit dosage forms, include, but are not limitedto powders, tablets, pills, capsules, lozenges, suppositories, patches,nasal sprays, injectables, implantable sustained-release formulations,lipid complexes, etc.

The agents (e.g. peptides, peptide mimetics, and/or lipids) of thisinvention are typically combined with a pharmaceutically acceptablecarrier (excipient) to form a pharmacological composition.Pharmaceutically acceptable carriers can contain one or morephysiologically acceptable compound(s) that act, for example, tostabilize the composition or to increase or decrease the absorption ofthe active agent(s). Physiologically acceptable compounds can include,for example, carbohydrates, such as glucose, sucrose, or dextrans,antioxidants, such as ascorbic acid or glutathione, chelating agents,low molecular weight proteins, protection and uptake enhancers such aslipids, compositions that reduce the clearance or hydrolysis of theactive agents, or excipients or other stabilizers and/or buffers.

Other physiologically acceptable compounds include wetting agents,emulsifying agents, dispersing agents or preservatives that areparticularly useful for preventing the growth or action ofmicroorganisms. Various preservatives are well known and include, forexample, phenol and ascorbic acid. One skilled in the art wouldappreciate that the choice of pharmaceutically acceptable carrier(s),including a physiologically acceptable compound depends, for example, onthe route of administration of the active agent(s) and on the particularphysio-chemical characteristics of the active agent(s).

The excipients are preferably sterile and generally free of undesirablematter. These compositions may be sterilized by conventional, well-knownsterilization techniques.

In therapeutic applications, the compositions of this invention areadministered to a patient suffering from one or more symptoms ofatherosclerosis or at risk for atherosclerosis in an amount sufficientto cure or at least partially prevent or arrest the disease and/or itscomplications. An amount adequate to accomplish this is defined as a“therapeutically effective dose.” Amounts effective for this use willdepend upon the severity of the disease and the general state of thepatient's health. Single or multiple administrations of the compositionsmay be administered depending on the dosage and frequency as requiredand tolerated by the patient. In any event, the composition shouldprovide a sufficient quantity of the active agents of the formulationsof this invention to effectively treat (ameliorate one or more symptoms)the patient.

The concentration of agent can vary widely, and will be selectedprimarily based on fluid volumes, viscosities, body weight and the likein accordance with the particular mode of administration selected andthe patient's needs. Concentrations, however, will typically be selectedto provide dosages ranging from about 0.1 or 1 mg/kg/day to about 50mg/kg/day and sometimes higher. Typical dosages range from about 3mg/kg/day to about 3.5 mg/kg/day, preferably from about 3.5 mg/kg/day toabout 7.2 mg/kg/day, more preferably from about 7.2 mg/kg/day to about11.0 mg/kg/day, and most preferably from about 11.0 mg/kg/day to about15.0 mg/kg/day. In certain preferred embodiments, dosages range fromabout 10 mg/kg/day to about 50 mg/kg/day. In certain embodiments,dosages range from about 20 mg to about 50 mg given orally twice daily.It will be appreciated that such dosages may be varied to optimize atherapeutic regimen in a particular subject or group of subjects.

In certain preferred embodiments, the (e.g. peptides, peptide mimetics,and/or lipids) of this invention are administered orally (e.g. via atablet) or as an injectable in accordance with standard methods wellknown to those of skill in the art. In other preferred embodiments, theagent(s), may also be delivered through the skin using conventionaltransdermal drug delivery systems, i.e., transdermal “patches” whereinthe active agent(s) are typically contained within a laminated structurethat serves as a drug delivery device to be affixed to the skin. In sucha structure, the drug composition is typically contained in a layer, or“reservoir,” underlying an upper backing layer. It will be appreciatedthat the term “reservoir” in this context refers to a quantity of“active ingredient(s)” that is ultimately available for delivery to thesurface of the skin. Thus, for example, the “reservoir” may include theactive ingredient(s) in an adhesive on a backing layer of the patch, orin any of a variety of different matrix formulations known to those ofskill in the art. The patch may contain a single reservoir, or it maycontain multiple reservoirs.

In one embodiment, the reservoir comprises a polymeric matrix of apharmaceutically acceptable contact adhesive material that serves toaffix the system to the skin during drug delivery. Examples of suitableskin contact adhesive materials include, but are not limited to,polyethylenes, polysiloxanes, polyisobutylenes, polyacrylates,polyurethanes, and the like. Alternatively, the drug-containingreservoir and skin contact adhesive are present as separate and distinctlayers, with the adhesive underlying the reservoir which, in this case,may be either a polymeric matrix as described above, or it may be aliquid or hydrogel reservoir, or may take some other form. The backinglayer in these laminates, which serves as the upper surface of thedevice, preferably functions as a primary structural element of the“patch” and provides the device with much of its flexibility. Thematerial selected for the backing layer is preferably substantiallyimpermeable to the active agent(s) and any other materials that arepresent.

Other preferred formulations for topical drug delivery include, but arenot limited to, ointments and creams. Ointments are semisolidpreparations which are typically based on petrolatum or other petroleumderivatives. Creams containing the selected active agent, are typicallyviscous liquid or semisolid emulsions, often either oil-in-water orwater-in-oil. Cream bases are typically water-washable, and contain anoil phase, an emulsifier and an aqueous phase. The oil phase, alsosometimes called the “internal” phase, is generally comprised ofpetrolatum and a fatty alcohol such as cetyl or stearyl alcohol; theaqueous phase usually, although not necessarily, exceeds the oil phasein volume, and generally contains a humectant. The emulsifier in a creamformulation is generally a nonionic, anionic, cationic or amphotericsurfactant. The specific ointment or cream base to be used, as will beappreciated by those skilled in the art, is one that will provide foroptimum drug delivery. As with other carriers or vehicles, an ointmentbase should be inert, stable, nonirritating and nonsensitizing.

Unlike typical peptide formulations, the peptides of this inventioncomprising D-form amino acids can be administered, even orally, withoutprotection against proteolysis by stomach acid, etc. Nevertheless, incertain embodiments, peptide delivery can be enhanced by the use ofprotective excipients. This is typically accomplished either bycomplexing the polypeptide with a composition to render it resistant toacidic and enzymatic hydrolysis or by packaging the polypeptide in anappropriately resistant carrier such as a liposome. Means of protectingpolypeptides for oral delivery are well known in the art (see, e.g.,U.S. Pat. No. 5,391,377 describing lipid compositions for oral deliveryof therapeutic agents).

Elevated serum half-life can be maintained by the use ofsustained-release protein “packaging” systems. Such sustained releasesystems are well known to those of skill in the art. In one preferredembodiment, the ProLease biodegradable microsphere delivery system forproteins and peptides (Tracy (1998) Biotechnol. Prog. 14: 108; Johnsonet al. (1996), Nature Med. 2: 795; Herbert et al. (1998), Pharmaceut.Res. 15, 357) a dry powder composed of biodegradable polymericmicrospheres containing the protein in a polymer matrix that can becompounded as a dry formulation with or without other agents.

The ProLease microsphere fabrication process was specifically designedto achieve a high protein encapsulation efficiency while maintainingprotein integrity. The process consists of (i) preparation offreeze-dried protein particles from bulk protein by spray freeze-dryingthe drug solution with stabilizing excipients, (ii) preparation of adrug-polymer suspension followed by sonication or homogenization toreduce the drug particle size, (iii) production of frozen drug-polymermicrospheres by atomization into liquid nitrogen, (iv) extraction of thepolymer solvent with ethanol, and (v) filtration and vacuum drying toproduce the final dry-powder product. The resulting powder contains thesolid form of the protein, which is homogeneously and rigidly dispersedwithin porous polymer particles. The polymer most commonly used in theprocess, poly(lactide-co-glycolide) (PLG), is both biocompatible andbiodegradable.

Encapsulation can be achieved at low temperatures (e.g., −40° C.).During encapsulation, the protein is maintained in the solid state inthe absence of water, thus minimizing water-induced conformationalmobility of the protein, preventing protein degradation reactions thatinclude water as a reactant, and avoiding organic-aqueous interfaceswhere proteins may undergo denaturation. A preferred process usessolvents in which most proteins are insoluble, thus yielding highencapsulation efficiencies (e.g., greater than 95%).

In another embodiment, one or more components of the solution can beprovided as a “concentrate”, e.g., in a storage container (e.g., in apremeasured volume) ready for dilution, or in a soluble capsule readyfor addition to a volume of water.

The foregoing formulations and administration methods are intended to beillustrative and not limiting. It will be appreciated that, using theteaching provided herein, other suitable formulations and modes ofadministration can be readily devised.

V. Kits for the Treatment of Conditions Characterized by ImpairedArteriole Structure and/or Function.

In another embodiment this invention provides kits for amelioration ofone or more symptoms of a pathology characterized by impaired arteriolestructure and/or function or for the prophylactic treatment of a subject(human or animal) at risk for such a condition. The kit(s) preferablycomprise a container containing one or more of the active agentsdescribed herein. The active agent(s) can be provided in a unit dosageformulation (e.g. suppository, tablet, caplet, patch, etc.) and/or maybe optionally combined with one or more pharmaceutically acceptableexcipients.

The kit(s) can, optionally, further comprise one or more other agentsused in the treatment of the condition/pathology of interest. Suchagents include, but are not limited to, beta blockers, vasodilators,aspirin, statins, ace inhibitors or ace receptor inhibitors (ARBs) andthe like, e.g. as described above.

In addition, the kits optionally include labeling and/or instructionalmaterials providing directions (i.e., protocols) for the practice of themethods or use of the “therapeutics” or “prophylactics” of thisinvention. Preferred instructional materials describe the use of one ormore active agent(s) of this invention to mitigate one or moreassociated with a condition characterized by impaired arteriolestructure and/or function and/or to prevent the onset or increase of oneor more of such symptoms in an individual at risk for such a condition.The instructional materials may also, optionally, teach preferreddosages/therapeutic regiment, counter indications and the like.

While the instructional materials typically comprise written or printedmaterials they are not limited to such. Any medium capable of storingsuch instructions and communicating them to an end user is contemplatedby this invention. Such media include, but are not limited to electronicstorage media (e.g., magnetic discs, tapes, cartridges, chips), opticalmedia (e.g., CD ROM), and the like. Such media may include addresses tointernet sites that provide such instructional materials.

EXAMPLES

The following examples are offered to illustrate, but not to limit theclaimed invention.

Example 1

As shown in FIGS. 1A, 1B, and 1C, mice with an absence of LDL receptors(LDLR−/−) have thickened brain arterioles compared to wild-type mice(WT). On a low fat chow diet the LDL receptor null mice have twice thelevel of plasma LDL of wild-type mice. However, they have very littleatherosclerosis on a chow diet but as shown in the figure below eventhough they have minimal atherosclerosis, their brain arterioles aresignificantly thickened. Also as shown in the following figures whenplaced on a high-fat, high-cholesterol (Western) diet, these micedevelop additional thickening of their brain arterioles. On the Westerndiet, these mice also develop extensive atherosclerosis.

It was recently reported that LDLR−/− mice have impaired spatial memoryassociated with a decreased synaptic density in the hippocampus (Mulderet al. (2004) Neurobiology of Disease 16: 212-219, see, e.g., FIG. 2therein).

As shown in FIG. 2, treatment of LDLR−/− mice on a Western diet for sixweeks with D-4F (added to the drinking water at 300 μg/mL) significantlyimproved the number of spontaneous alterations in the T-maze test whileadding the same concentration of the control peptide (scrambled D-4F)did not.

The results shown in FIG. 2 for the mice receiving D-4F compared to thecontrol peptide are remarkably similar to those shown in FIG. 2 fromMulder et al. (supra.) where LDLR−/− mice were compared to wild-typemice (LDLR+/+) suggesting that oral D-4F reversed the abnormality in theLDLR−/− mice. The data in the figure from Mulder et al. are shown as“percentage alternation”. The data in FIG. 2, herein, are shown for“Number of Spontaneous Alternations”. As shown in FIG. 3 below the datawith D-4F compared to scrambled D-4F are similar when presented as“Percentage Alternation

Further evidence of the improvement in the T-maze test with D-4Ftreatment compared to the control peptide, scrambled D-4F (Sc D-4F)comes from the data in FIG. 4.

It was previously reported that injection of D-4F improvedvasoreactivity of facial arteries (Ou Z, Ou J, Ackerman A W et al. L-4F,an apolipoprotein A-I mimetic, restores nitric oxide and superoxideanion balance in low-density lipoprotein-treated endothelial cells. Ouet al. (2003) Circulation; 107: 1520-1524; Ou et al. (2003) Circulation107: 2337-2341). In these published studies the mouse facial artery wasused. This artery has an internal diameter of about 250 μM.

Another example of the application of this invention comes from the datashown below in FIG. 5 which show that administering DMPC orally to LDLreceptor null mice on a Western diet improved the vasoreactivity oftheir facial arteries significantly better than administering soylecithin.

Eight week old female LDL receptor null mice were maintained on aWestern diet and given drinking water alone (Control, n=6) or weremaintained on a Western diet and given drinking water supplemented with1 mg/mL of either soy lecithin (n=6), or DMPC (n=6). After six weeks thesubmandibular segment of the facial artery was dissected out and thepercent relaxation of the preconstricted 2 mm arterial rings wasdetermined in response to the addition of acetylcholine (anendothelium-dependent relaxant) in concentrations ranging from 0.01 to10 μM. The specificity of the relaxation was confirmed by addition of300 μM L-NAME (a nitric oxide synthase inhibitor) and sodiumnitroprusside (an endothelium-independent nitric oxide donor). There wasno difference between groups with addition of L-NAME (which inhibitedthe vasorelaxation elicited by acetylcholine) and sodium nitroprussideor papaverine (which maximally vasodilated). In the absence of theseadditions there was a marked inhibition in acetylcholine vasorelaxationin the Control group. There was a trend toward improved relaxation inthe soy lecithin group but this did not reach statistical significance.There was a significant improvement in vasorelaxation in the mice thatreceived DMPC (p<0.01 at 1 μM acetylcholine; p<0.001 at 10 μMacetylcholine). The Log of the acetylcholine concentration producing 50%vasorelaxation (Log EC50 in mM) was 0.473 for the Control group, 0.057for the group receiving soy lecithin, and 0.006 for the group receivingDMPC.

We have previously published that administering DMPC to apoe null micecaused an increase in plasma apoA-I levels and HDL-cholesterol,resulting in sequestration/removal/destruction of inflammatory lipidsand conversion of HDL from pro-inflammatory to anti-inflammatory withboth prevention and regression of atherosclerosis in this mouse model(Navab M, Hama S, Hough G et al. Oral synthetic phospholipids (DMPC)raises high-density lipoprotein cholesterol levels, improveshigh-density lipoprotein function, and markedly reduces atherosclerosisin apolipoprotein E-null mice. Circulation 2003; 108:1735-1739).

Thus, we have shown that two different agents thatsequester/remove/destroy inflammatory lipids (D-4F and DMPC) one an oralpeptide and one a oral phospholipids that increases apoA-I and HDLcholesterol both improve arterial function as measured in a smallartery, the facial artery, The novel findings of this invention relateto a method for improving the structure and function of vessels smallerthan even small arteries, i.e. arterioles. These arterioles areultimately responsible for the perfusion of tissues as diverse as brainand kidney. Based on data shown herein and unpublished data, we believethis invention provides a general method to improve the structure andfunction of arterioles by administering agents thatsequester/remove/destroy inflammatory lipids and convertpro-inflammatory high density lipoproteins (HDL) to anti-inflammatory orrender anti-inflammatory HDL more anti-inflammatory. These agentsinclude peptides containing a class A amphipathic helix, peptidescontaining a G* amphipathic helix, short peptides and non-peptides witha molecular weight of less than 900 daltons that have a solubility inethyl acetate of at least 4 mg/mL, and which are soluble in aqueousbuffer at pH 7.0 and when contacted with a phospholipid in an aqueousenvironment, form particles with a diameter of approximately 7.5 nm andform stacked bilayers with a bilayer dimension on the order of 3.4 to4.1 nm with spacing between the bilayers in the stack of approximately 2nm; and oral synthetic phospholipids in which the sn-1 and sn-2positions are identical and contain at least 3 carbons.

Example 2 ApoA-1 Mimetic Peptide D-4F Reduces Brain Arteriolar WallThickening and Improves Spatial Memory in LDL Receptor Null Mice Fed aWestern Diet Summary

The wall thickness of brain arterioles 10-100 μm in diameter wasdetermined in wild-type and LDL-receptor null C57BL/6 mice on chow or aWestern diet administered alone or with D-4F or scrambled D-4F. Spatialmemory was determined by use of the T-maze continuous alternation task.On chow, brain arteriolar wall thickness in LDL receptor null mice wasincreased compared to wild-type and further increased on the Westerndiet (p<0.001). The increased brain arteriolar wall thickness was inpart due to an increase in smooth muscle α-actin content and wasdecreased by treatment with D-4F but not scrambled D-4F. Adding theWestern diet significantly impaired performance in the T-maze (p<0.05)and was improved with D-4F compared to scrambled D-4F (p<0.05). Thechanges in performance and in arteriolar wall thickness were independentof plasma lipids and arteriolar lumen diameter.

Treatment of LDL-receptor null mice fed a Western Diet with D-4F reducesbrain arteriolar wall thickness independent of plasma lipids andarteriolar lumen diameter and improves spatial memory.

Materials and Methods

Materials

D-4F and scrambled D-4F (a peptide with the same D-amino acids as inD-4F but arranged in a sequence which prevents the peptide fromachieving the helical conformation needed for lipid binding) weresynthesized as previously described (Navab et al. (2002) Circulation,105: 290-292; Navab et al. (2004) Circulation, 109:r120-r125). All otherreagents were from sources previously reported (Navab et al. (2005)Arterioscler Thromb Vasc Biol., 25: 1-7).

Mice and Histopathology

Female wild-type and LDL receptor null C57BL/6 mice were from JacksonLaboratories (Bar Harbour, Me.). The mice were maintained on a chow diet(Ralston Purina) prior to administration of a Western diet(Teklad/Harlan, Madison Wis., diet No. 88137; 42% fat, 0.15%cholesterol, w/w). For studies of brain arterioles the mice wereanesthetized with intramuscular ketamine (100 mg/kg) and acepromazine(2.5 mg/kg) and the heart was perfused via the left ventricle with 25 mLphosphate buffered saline (PBS) containing heparin (10 U/mL) followed by100 mL of 4% paraformaldehyde (PFA) in PBS at pH 7.4 as described byFernagut et al. (Fernagut et al. (2002) Neuroscience, 114: 1005-1017;Fernagut et al. (2004) Exp Neurol., 185: 47-62). Brains were quicklyremoved and stored for 24 hrs in 4% PFA at 4° C. and then transferred to10% sucrose in PBS (pH 7.4) and left until they sank to the bottom ofthe solution. The right half of the brains were embedded in OCT(Tissue-Tek; Miles Laboratories Ltd, Elkhart Ind.) and frozen inisopentane at −40° C. and stored at −80° C. until sectioned in acryostat at −20° C. The frozen brain was cut into 8 μm sectionscoronally to include the underlying white matter and stained withhematoxylin-eosin (H&E) and for smooth muscle α-actin (Serotec, Raleigh,N.C.). The left half of each brain was embedded in paraffin, cutcoronally into 6 μm thick sections and stained with H&E. The UCLA AnimalResearch Committee approved all studies.

Morphometry and Associated Statistical Methods

Morphometry was performed to determine vascular wall thickness for allarterioles that were distended and perpendicularly cross-sectioned.Using a 40× microscope objective, the sectioned vessels werephotographed using SPOT Image software and three measurements of theinternal and external diameters were taken for each and averaged. Therange of vessels sizes were between 10 and 160 μm and the comparison ofwall to lumen ratios was made separately for arteries with internaldiameter values of 10-20 μm, 21-50 μm, 51-100 μm and >100 μm. A minimumof 10 arteries from each diameter group was examined in the corticalarea and the deep white matter regions from each brain, and the wallthickness and wall to lumen ratios determined. The ratio ofimmunoreactive media thickness to the internal diameter of each vesselwas assessed in sections immunostained for smooth muscle α-actin. Allmeasurements were performed on a single focal plane using an OlympusBH-2 microscope equipped with a 40× lens by one investigator andrepeated by two observers blinded to treatment. Inter-observer variationwas determined by having the three investigators measure the same 20arterioles for wall thickness and lumen diameter and calculate the wallto lumen ratio. The coefficient of variation was found to be 14±1%. Alldata were computed using InStat and Prism software (Graphpad, San Diego,Calif., U.S.A.). Statistical significance of difference between means ofdifferent groups was performed using unpaired student t-test or one-wayANOVA. Multiple comparisons of the different groups were performed usingTukey-Kramer multiple comparisons test. A probability level of 5%(p<0.05) was considered significant.

Behavioral Studies and Associated Statistical Methods

T-maze continuous alternation task (T-CAT) testing took place dailybetween 9 A.M. and 4 P.M. and was performed by one investigator unawareof the treatment groups. The mice were delivered to the testing room twohours prior to behavioral studies to allow familiarization with theextra-maze visual cues of the room. The T-maze apparatus used in ourstudies is identical to the one described by Gerlai et al. (Gerlai(1998) Behavioural Brain Research, 95: 91-101) and was made oftransparent acrylic walls with a black acrylic bottom. The dimensions ofstart and goal arms were: length 75 cm, width 12 cm and height 20 cm.The maze was equipped with three removable guillotine doors that couldbe operated by manual remote control. The testing room was illuminatedby ceiling and floor lights and a fan provided a constant backgroundnoise. The T-maze was separated from the investigator by a black curtainand the movement of the mice in the maze was observed on a TV monitorand videotaped. After each individual mouse the T-maze was carefullycleaned with Windex spray and dried with paper towels. The T-mazecontinuous alternation task (T-CAT) limits the handling of mice andpermits their exploratory behavior to be carried out undisturbed. Theprocedure used in this study is identical to that described by Gerlai etal. (Id.) and consisted of one forced and 14 free choice trials.Consecutive choices made by the mice were measured and the alternationrate during the 14 free choice trials was calculated (0%-no alternation,100%-alternation at each trial, 50%-random choice). The time (inseconds) needed to complete the 15 trials was recorded and analyzed. TheT-CAT testing was continuously registered by a video tracking system (SDInstruments Inc., San Diego, Calif.) and stored on a computer.Statistics were performed using StatView software (SAS Institute, Cary,N.C.)

Other Procedures

Plasma lipoprotein and lipid levels were determined as describedpreviously (Navab et al. (2004) Circulation, 109:r120-r125; Navab et al.(2005) Arterioscler Thromb Vasc Biol., 25: 1-7).

Results

Brain Arteriolar Wall Thickness is Increased in LDL Receptor Null Miceand is Further Increased with Addition of the Western Diet

As shown in FIG. 6 on a chow diet arteriolar wall thickness was greaterin LDL receptor null mice compared to wild-type mice and after a Westerndiet for six weeks arteriolar wall thickness was further increased inthe LDL receptor null mice.

Brain Arteriolar Wall Thickness is Reduced by Treatment with D-4F butnot with Scrambled D-4F

FIGS. 7A-7C demonstrate that adding 300 μg/mL of D-4F to the drinkingwater of LDL receptor null mice on a Western diet for 6 weeks resultedin reduced brain arteriolar wall thickness compared to adding the sameconcentration of scrambled D-4F to the drinking water. FIG. 7Ddemonstrates that there was no difference in the lumen diameters of thebrain arterioles between mice receiving D-4F or scrambled D-4F. Someinvestigators have argued that the most reliable measurement ofarteriole wall thickness is obtained by dividing the wall thickness foreach arteriole by the lumen diameter for that arteriole (Mulvany (1999)Cardiovascular Research, 41: 9-13). FIGS. 7E-7G demonstrate that theratio of wall to lumen diameter was significantly less in mice receivingD-4F compared to scrambled D-4F. There was no significant difference inthe concentrations of plasma total cholesterol, LDL-cholesterol,HDL-cholesterol, or triglycerides when the mice were administered D-4Fcompared to scrambled D-4F. The total cholesterol concentrations were1,076±75 (Mean±SEM) for mice receiving D-4F compared to 970±61 mg/dL formice receiving scrambled D-4F. LDL and HDL cholesterol concentrationswere 924±76 and 86±6 mg/dL, respectively, for mice receiving D-4Fcompared to 834±63 and 79±5 mg/dL, respectively, for the mice receivingscrambled D-4F. Triglycerides were 330±25 compared to 288±25 mg/dL formice receiving D-4F or scrambled D-4F, respectively.

Brain Arteriolar Wall Thickening is in Part Due to an Increase in SmoothMuscle α-actin Content

As shown in FIG. 8A administration of the Western diet to LDL receptornull mice resulted in a significant increase in the amount of smoothmuscle α-actin in the walls of the brain arterioles of LDL receptor nullmice fed a Western diet. FIG. 8B shows representative brain arteriolesstained for smooth muscle cell α-actin from mice that were treated withD-4F or scrambled D-4F. FIGS. 8C-8E demonstrate quantitatively thattreatment of the mice with D-4F significantly reduced brain arteriolarwall smooth muscle α-actin content compared to mice treated withscrambled D-4F.

Feeding LDL Receptor Null Mice a Western Diet Results in ImpairedSpatial Memory, which is Significantly Improved by Treatment with D-4Fbut Not Scrambled D-4F.

FIGS. 9A-9D demonstrate that when the LDL receptor null mice describedin FIG. 3A were placed on a Western diet they had impaired spatialmemory as measured with the T-CAT. FIGS. 9E-9G demonstrate thattreatment with oral D-4F (but not scrambled D-4F) of the mice describedin FIGS. 7 and 8B-8E significantly improved performance as measured withthe T-CAT. Although the mice receiving scrambled D-4F required more timethan the mice that received D-4F to complete the 15 trials (579±23seconds vs. 548±37 seconds, respectively) this difference did not reachstatistical significance. Nonetheless, the data in FIGS. 9E-9G clearlydemonstrate improvement with D-4F treatment.

2. Discussion

The data presented in this example together with that previouslypublished⁸⁻¹⁰ suggest that LDL levels affect all branches of thearterial tree in mice. On a chow diet the LDL receptor null mice hadsignificantly increased arteriole wall thickness in brain arterioleswith lumens of 15-40 μm in diameter (FIG. 6A). After only six weeks on aWestern diet there was a significant increase in the wall thickness ofbrain arterioles in these LDL receptor null mice compared to wild-typemice (FIG. 6A-6C).

Heistad and colleagues (Heistad et al. (1995) Hypertension, 26: 509-513)emphasized the differences and similarities in atherosclerotic andhypertensive vessels. These authors made the observation that “Changesin vascular structure in both atherosclerosis and hypertension arecharacterized by thickening of the vessel wall and vascular‘remodeling’.” Remodeling tends to preserve the size of the lumen inatherosclerotic vessels and results in a smaller lumen in hypertensivevessels.” As shown in FIG. 7D it appears that the thickening of brainarterioles in LDL receptor null mice induced by the Western diet (fedfor six weeks) can be independent of changes in lumen diameter. We didnot measure blood pressure in these mice and we do not know if the lumendiameters would be altered by a longer period of exposure. However, itis clear that within a period of only six weeks the wall to lumen ratioof brain arterioles as determined by smooth muscle cell α-actin contentwas significantly increased with feeding of the Western diet (FIG. 8A).

It has long been known that LDL enriched in reactive oxygen species canstimulate vascular smooth muscle cell growth (Gorog (1997)Atherosclerosis, 129: 1-7). It has also been reported that mice withincreased oxidative stress because of a deficiency in cystathionineα-synthase have cerebral vascular hypertrophy with increased smoothmuscle content in their brain arterioles (Baumbach et al. (2002) CircRes, 91: 931-937). It is tempting to speculate that treatment with oralD-4F, which is known to decrease LDL lipid hydroperoxides in micewithout changing plasma lipid levels (Navab et al. (2004) Circulation,109:r120-r125)¹, might have ameliorated the increase in brain arteriolarsmooth muscle α-actin (FIGS. 8B-8E) by reducing lipoprotein lipidhydroperoxides without changing plasma lipids.

Mulder et al. (Mulder et al. (2004) Neurobiology of Disease, 16:212-219) first reported that LDL receptor null mice on a chow dietcompared to wild-type mice on a chow diet have impaired spatial memory.These authors concluded that the abnormality was similar to thatreported in apoe null mice (Kfugers et al. (1997) Neruo Report, 8:2505-2510; Oitzl et al. (1997) Brain Res., 752: 189-196; Zhou et al.(1998) Brain Res., 788:151-159; Veinbergs et al. (1999) Neuroscience91:401-403; Krzywkowski et al. (1999) Neuroscience 92:1273-1286; Raberet al. (2000) Nature 404:352-354) and was due to a primary abnormalityin brain cells induced by a failure to provide lipoprotein constituentsto the brain cells. The data reported here in FIG. 9 together with thatin FIGS. 6-8, suggest an alternative hypothesis. The primary abnormalitymay be due in part or entirely to the “Sick Vessel Syndrome” describedby Heistad et al. (1995) Hypertension, 26: 509-513, and not to thefailure to deliver lipoprotein constituents to brain cells. In favor ofthis hypothesis is the worsening of the functional defect with theworsening of the hyperlipidemia (FIGS. 9A-9D). If the primary defectwere due to a lack of lipoprotein constituents delivered to brain cellsbecause of an absence of LDL receptors, one would have expectedimprovement in function with increased plasma lipoprotein levels sincedelivery of lipoproteins into the brain cells by non-receptor-mediatedpathways would likely increase with increasing hyperlipidemia. Furthersupport for a vascular basis for the functional abnormalities noted inFIG. 9 is the correlation between the functional abnormalities and thestructural changes in arterioles which were worsened by the Western diet(FIGS. 6 and 8A) and improved by oral D-4F (but not scrambled D-4F)(FIGS. 7 and 8B-8E). We did not measure brain arteriole vasoreactivityin these mice. However, Pritchard and colleagues found thatvasoreactivity in the facial artery (approximately 240 μm in diameter)of LDL receptor null mice was severely impaired by a Western diet andwas dramatically improved with 4F treatment (Ou et al. (2003)Circulation, 107: 2337-2341; Ou et al. (2005) Circulation Research 97:1190-1197. Heistad and colleagues (Heistad et al. (1980) Am. J. Physiol.239 (Heart Circ. Physiol. 8):H539-H544) reported that in monkeys madehypercholesterolemic by feeding an atherogenic diet maximal cerebralvasodilator responses to hypercapnia were impaired, but during a lesspronounced vasodilator stimulus autoregulatory responses to hypotensionwere preserved. Interestingly, when the monkeys were put on a regressiondiet and subjected to maximal vasodilation, the responsiveness of thecerebral arterial bed was significantly improved (Armstrong et al.(1983). J. Clin. Invest., 71: 104-113).

It is interesting to note that it has been observed in humans sufferingfrom the angiopathy of subcortical arteriosclerotic encephalopathy(Binswanger's disease) that there is an increase in smooth muscleα-actin in brain vessels smaller than 100 μm in diameter (Lin et al.(2000) Stroke, 31:1838-1842). It is also tempting to speculate that the“Sick Vessel Syndrome” may play a broader role in human dementias thanhas been previously recognized and that the use of apoA-I mimeticpeptides such as D-4F may have beneficial effects in such diseases.

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to persons skilled in the art and areto be included within the spirit and purview of this application andscope of the appended claims. All publications, patents, and patentapplications cited herein are hereby incorporated by reference in theirentirety for all purposes.

1. A method of improving arteriole structure and/or function, saidmethod comprising: administering to a mammal in need thereof one or moreof the peptides described in Tables 1-14 or the retro, inverso, orretro-inverso forms of these peptides in a dosage sufficient to improvearteriole structure or function.
 2. The method of claim 1, wherein saidarteriole is an arteriole in a kidney.
 3. The method of claim 1, whereinsaid arteriole is an arteriole in a brain.
 4. The method of claim 1,wherein said mammal is a human.
 5. The method of claim 1, wherein saidmammal is a human diagnosed as having memory loss or impaired learning.6. The method of claim 1, wherein said mammal is a human diagnosed ashaving impaired kidney function.
 7. The method of claim 1, wherein saidmammal is a human diagnosed as having impaired alveolar function.
 8. Themethod of claim 1, wherein said mammal is a human not diagnosed ashaving or at risk for atherosclerosis.
 9. The method of claim 1, whereinsaid peptide is in a unit dosage formulation.
 10. The method of claim 1,wherein the peptide(s) are formulated for administration by a routeselected from the group consisting of oral administration, nasaladministration, rectal administration, intraperitoneal injection, andintravascular injection, subcutaneous injection, transcutaneousadministration, and intramuscular injection.
 11. The method of claim 1,wherein said administration is by a route selected from the groupconsisting of oral administration, nasal administration, rectaladministration, intraperitoneal injection, and intravascular injection,subcutaneous injection, transcutaneous administration, and intramuscularinjection.
 12. The method of claim 1, wherein said peptide(s) areselected from the group consisting of D4F, L4F, reverse D4F, and reverseL4F.
 13. The method of claim 1, wherein said active agent(s) areprovided in combination with a pharmaceutically acceptable excipient.14. The method of claim 1, wherein said active agent(s) are provided ina unit dosage formulation.
 15. A kit for the treatment of a conditioncharacterized by abnormal arteriole structure or function, said kitcomprising: a container containing one or more of the active agentsdescribed in Tables 1-14 or the retro, inverso, or retro-inverso formsof these peptides; and instructional materials teaching the use of thepeptide(s) in the treatment of a condition characterized by abnormalarteriole structure or function.
 16. The kit of claim 15, wherein saidpeptide is in a unit dosage formulation.
 17. The kit of claim 15,wherein the peptide(s) are formulated for administration by a routeselected from the group consisting of oral administration, nasaladministration, rectal administration, intraperitoneal injection, andintravascular injection, subcutaneous injection, transcutaneousadministration, and intramuscular injection.
 18. The kit of claim 15,wherein said active agent(s) are selected from the group consisting ofD4F, L4F, reverse D4F, reverse L4F, and DMPC.